WO2015053413A1 - ドライバーオンコジーンの遺伝子変異を標的にアルキル化する新規アルキル化剤 - Google Patents
ドライバーオンコジーンの遺伝子変異を標的にアルキル化する新規アルキル化剤 Download PDFInfo
- Publication number
- WO2015053413A1 WO2015053413A1 PCT/JP2014/077766 JP2014077766W WO2015053413A1 WO 2015053413 A1 WO2015053413 A1 WO 2015053413A1 JP 2014077766 W JP2014077766 W JP 2014077766W WO 2015053413 A1 WO2015053413 A1 WO 2015053413A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gene
- cells
- complex
- dna
- cancer
- Prior art date
Links
- 108700020796 Oncogene Proteins 0.000 title claims abstract description 63
- 239000002168 alkylating agent Substances 0.000 title claims abstract description 43
- 229940100198 alkylating agent Drugs 0.000 title claims abstract description 43
- 230000002152 alkylating effect Effects 0.000 title claims description 8
- 230000035772 mutation Effects 0.000 title abstract description 114
- 239000004952 Polyamide Substances 0.000 claims abstract description 24
- 229920002647 polyamide Polymers 0.000 claims abstract description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 22
- 230000027455 binding Effects 0.000 claims abstract description 11
- 108020004705 Codon Proteins 0.000 claims description 63
- 101150105104 Kras gene Proteins 0.000 claims description 58
- 108090000623 proteins and genes Proteins 0.000 claims description 56
- 108020004414 DNA Proteins 0.000 claims description 55
- 150000001875 compounds Chemical class 0.000 claims description 48
- 101150022024 MYCN gene Proteins 0.000 claims description 42
- 206010064571 Gene mutation Diseases 0.000 claims description 39
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 38
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 24
- 238000004519 manufacturing process Methods 0.000 claims description 23
- -1 c-KIT Proteins 0.000 claims description 22
- 108700012912 MYCN Proteins 0.000 claims description 21
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 claims description 21
- 102000039446 nucleic acids Human genes 0.000 claims description 20
- 108020004707 nucleic acids Proteins 0.000 claims description 20
- 150000007523 nucleic acids Chemical class 0.000 claims description 20
- 101150063858 Pik3ca gene Proteins 0.000 claims description 19
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 claims description 18
- 101150040459 RAS gene Proteins 0.000 claims description 18
- 102100030708 GTPase KRas Human genes 0.000 claims description 17
- 239000002246 antineoplastic agent Substances 0.000 claims description 13
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 13
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 13
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 13
- 102200003102 rs863225281 Human genes 0.000 claims description 13
- 102000052510 DNA-Binding Proteins Human genes 0.000 claims description 11
- 230000004568 DNA-binding Effects 0.000 claims description 11
- 230000008859 change Effects 0.000 claims description 11
- 101150023956 ALK gene Proteins 0.000 claims description 10
- 101150076031 RAS1 gene Proteins 0.000 claims description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims description 10
- 102000016914 ras Proteins Human genes 0.000 claims description 10
- 101710096438 DNA-binding protein Proteins 0.000 claims description 9
- 238000011160 research Methods 0.000 claims description 9
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 claims description 8
- 101000779641 Homo sapiens ALK tyrosine kinase receptor Proteins 0.000 claims description 8
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 claims description 7
- 102100029974 GTPase HRas Human genes 0.000 claims description 7
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 claims description 7
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims description 7
- 239000002131 composite material Substances 0.000 claims description 7
- 125000000524 functional group Chemical group 0.000 claims description 7
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims description 6
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims description 6
- 108091012583 BCL2 Proteins 0.000 claims description 6
- 102000036365 BRCA1 Human genes 0.000 claims description 6
- 108700020463 BRCA1 Proteins 0.000 claims description 6
- 101150072950 BRCA1 gene Proteins 0.000 claims description 6
- 102000038594 Cdh1/Fizzy-related Human genes 0.000 claims description 6
- 108091007854 Cdh1/Fizzy-related Proteins 0.000 claims description 6
- 102100034157 DNA mismatch repair protein Msh2 Human genes 0.000 claims description 6
- 102100021147 DNA mismatch repair protein Msh6 Human genes 0.000 claims description 6
- 101150029707 ERBB2 gene Proteins 0.000 claims description 6
- 102100039788 GTPase NRas Human genes 0.000 claims description 6
- 101001134036 Homo sapiens DNA mismatch repair protein Msh2 Proteins 0.000 claims description 6
- 101000968658 Homo sapiens DNA mismatch repair protein Msh6 Proteins 0.000 claims description 6
- 101000582631 Homo sapiens Menin Proteins 0.000 claims description 6
- 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 claims description 6
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 claims description 6
- 101000695187 Homo sapiens Protein patched homolog 1 Proteins 0.000 claims description 6
- 101000579425 Homo sapiens Proto-oncogene tyrosine-protein kinase receptor Ret Proteins 0.000 claims description 6
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims description 6
- 101000742859 Homo sapiens Retinoblastoma-associated protein Proteins 0.000 claims description 6
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims description 6
- 101000628562 Homo sapiens Serine/threonine-protein kinase STK11 Proteins 0.000 claims description 6
- 229910015837 MSH2 Inorganic materials 0.000 claims description 6
- 102100030550 Menin Human genes 0.000 claims description 6
- 108010074346 Mismatch Repair Endonuclease PMS2 Proteins 0.000 claims description 6
- 102000008071 Mismatch Repair Endonuclease PMS2 Human genes 0.000 claims description 6
- 102000013609 MutL Protein Homolog 1 Human genes 0.000 claims description 6
- 108010026664 MutL Protein Homolog 1 Proteins 0.000 claims description 6
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims description 6
- 102000048850 Neoplasm Genes Human genes 0.000 claims description 6
- 108700019961 Neoplasm Genes Proteins 0.000 claims description 6
- 108091007960 PI3Ks Proteins 0.000 claims description 6
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 claims description 6
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 claims description 6
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 claims description 6
- 102100028680 Protein patched homolog 1 Human genes 0.000 claims description 6
- 102100028286 Proto-oncogene tyrosine-protein kinase receptor Ret Human genes 0.000 claims description 6
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims description 6
- 102100038042 Retinoblastoma-associated protein Human genes 0.000 claims description 6
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims description 6
- 102100026715 Serine/threonine-protein kinase STK11 Human genes 0.000 claims description 6
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 claims description 6
- 230000004544 DNA amplification Effects 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 102100030124 N-myc proto-oncogene protein Human genes 0.000 claims 2
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 claims 2
- 210000004027 cell Anatomy 0.000 description 227
- 206010028980 Neoplasm Diseases 0.000 description 94
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 69
- 201000011510 cancer Diseases 0.000 description 55
- 206010009944 Colon cancer Diseases 0.000 description 28
- 206010029260 Neuroblastoma Diseases 0.000 description 27
- 230000030833 cell death Effects 0.000 description 25
- 239000002609 medium Substances 0.000 description 24
- 238000000034 method Methods 0.000 description 23
- 238000011282 treatment Methods 0.000 description 22
- 238000005804 alkylation reaction Methods 0.000 description 20
- 239000003814 drug Substances 0.000 description 20
- 238000002474 experimental method Methods 0.000 description 20
- 230000014509 gene expression Effects 0.000 description 20
- 230000002401 inhibitory effect Effects 0.000 description 20
- 102000055056 N-Myc Proto-Oncogene Human genes 0.000 description 19
- 230000029936 alkylation Effects 0.000 description 19
- 230000015572 biosynthetic process Effects 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- 208000029742 colonic neoplasm Diseases 0.000 description 18
- 230000003321 amplification Effects 0.000 description 17
- 238000003199 nucleic acid amplification method Methods 0.000 description 17
- 238000003786 synthesis reaction Methods 0.000 description 17
- 201000010099 disease Diseases 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 206010006187 Breast cancer Diseases 0.000 description 15
- 208000026310 Breast neoplasm Diseases 0.000 description 15
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 15
- 238000005259 measurement Methods 0.000 description 15
- 229940079593 drug Drugs 0.000 description 14
- 238000004128 high performance liquid chromatography Methods 0.000 description 14
- 238000011580 nude mouse model Methods 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 230000008685 targeting Effects 0.000 description 13
- 239000000047 product Substances 0.000 description 12
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 11
- 241000699660 Mus musculus Species 0.000 description 11
- 230000010261 cell growth Effects 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 10
- 229910002091 carbon monoxide Inorganic materials 0.000 description 10
- 238000012790 confirmation Methods 0.000 description 10
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 10
- 210000004940 nucleus Anatomy 0.000 description 10
- 229920006395 saturated elastomer Polymers 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 230000004614 tumor growth Effects 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 230000005778 DNA damage Effects 0.000 description 9
- 231100000277 DNA damage Toxicity 0.000 description 9
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 8
- 230000004663 cell proliferation Effects 0.000 description 8
- 201000005202 lung cancer Diseases 0.000 description 8
- 208000020816 lung neoplasm Diseases 0.000 description 8
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 8
- 201000002528 pancreatic cancer Diseases 0.000 description 8
- 208000008443 pancreatic carcinoma Diseases 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 229930024421 Adenine Natural products 0.000 description 7
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 7
- 102000052575 Proto-Oncogene Human genes 0.000 description 7
- 108700020978 Proto-Oncogene Proteins 0.000 description 7
- 208000024770 Thyroid neoplasm Diseases 0.000 description 7
- 239000000654 additive Substances 0.000 description 7
- 229960000643 adenine Drugs 0.000 description 7
- 231100000263 cytotoxicity test Toxicity 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 102000053602 DNA Human genes 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 6
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical group NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 102000043276 Oncogene Human genes 0.000 description 5
- 201000000582 Retinoblastoma Diseases 0.000 description 5
- 230000035508 accumulation Effects 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 229940000635 beta-alanine Drugs 0.000 description 5
- 238000010609 cell counting kit-8 assay Methods 0.000 description 5
- 230000022131 cell cycle Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000005945 translocation Effects 0.000 description 5
- 206010071977 Anaplastic lymphoma kinase gene mutation Diseases 0.000 description 4
- 206010014733 Endometrial cancer Diseases 0.000 description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 206010053759 Growth retardation Diseases 0.000 description 4
- 108091093037 Peptide nucleic acid Proteins 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 231100000480 WST assay Toxicity 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000013467 fragmentation Methods 0.000 description 4
- 238000006062 fragmentation reaction Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 125000005647 linker group Chemical group 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 102200006531 rs121913529 Human genes 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 4
- 201000002510 thyroid cancer Diseases 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- 0 CC(C1)C*(C)C1C(C)=O Chemical compound CC(C1)C*(C)C1C(C)=O 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 206010048832 Colon adenoma Diseases 0.000 description 3
- 241001634576 Colona Species 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- 230000018199 S phase Effects 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- 230000037429 base substitution Effects 0.000 description 3
- 210000000941 bile Anatomy 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000030570 cellular localization Effects 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000037437 driver mutation Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 201000010536 head and neck cancer Diseases 0.000 description 3
- 208000014829 head and neck neoplasm Diseases 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 102000004296 ribosomal protein S18 Human genes 0.000 description 3
- 108090000842 ribosomal protein S18 Proteins 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- 206010043688 thyroid adenoma Diseases 0.000 description 3
- 210000001685 thyroid gland Anatomy 0.000 description 3
- 239000003656 tris buffered saline Substances 0.000 description 3
- 230000036326 tumor accumulation Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- ZPOROQKDAPEMOL-UHFFFAOYSA-N 1h-pyrrol-3-ol Chemical compound OC=1C=CNC=1 ZPOROQKDAPEMOL-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 206010069754 Acquired gene mutation Diseases 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 206010061764 Chromosomal deletion Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 102000018898 GTPase-Activating Proteins Human genes 0.000 description 2
- 108091006094 GTPase-accelerating proteins Proteins 0.000 description 2
- 208000034951 Genetic Translocation Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010067218 Guanine Nucleotide Exchange Factors Proteins 0.000 description 2
- 102000016285 Guanine Nucleotide Exchange Factors Human genes 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 238000011530 RNeasy Mini Kit Methods 0.000 description 2
- 241000978776 Senegalia senegal Species 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000010805 cDNA synthesis kit Methods 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 230000032677 cell aging Effects 0.000 description 2
- 230000025084 cell cycle arrest Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 229940105990 diglycerin Drugs 0.000 description 2
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000011503 in vivo imaging Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- QQVIHTHCMHWDBS-UHFFFAOYSA-N isophthalic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002370 liquid polymer infiltration Methods 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 238000011866 long-term treatment Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 150000003233 pyrroles Chemical class 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- YZHUMGUJCQRKBT-UHFFFAOYSA-M sodium chlorate Chemical compound [Na+].[O-]Cl(=O)=O YZHUMGUJCQRKBT-UHFFFAOYSA-M 0.000 description 2
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 2
- VSIVTUIKYVGDCX-UHFFFAOYSA-M sodium;4-[2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].COC1=CC([N+]([O-])=O)=CC=C1[N+]1=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=NN1C1=CC=C([N+]([O-])=O)C=C1 VSIVTUIKYVGDCX-UHFFFAOYSA-M 0.000 description 2
- 230000037439 somatic mutation Effects 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 230000005760 tumorsuppression Effects 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- GHSXIZYVEWSKER-UHFFFAOYSA-N 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indol-5-ol Chemical compound C12=CC=CC=C2C(O)=CC2=C1C(CCl)CN2 GHSXIZYVEWSKER-UHFFFAOYSA-N 0.000 description 1
- OXHNLMTVIGZXSG-UHFFFAOYSA-N 1-Methylpyrrole Chemical group CN1C=CC=C1 OXHNLMTVIGZXSG-UHFFFAOYSA-N 0.000 description 1
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical group CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 description 1
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 206010061692 Benign muscle neoplasm Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 208000028006 Corneal injury Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 230000007118 DNA alkylation Effects 0.000 description 1
- 230000000970 DNA cross-linking effect Effects 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010061825 Duodenal neoplasm Diseases 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 108020005004 Guide RNA Proteins 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 201000004458 Myoma Diseases 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 239000012828 PI3K inhibitor Substances 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 description 1
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 102000009609 Pyrophosphatases Human genes 0.000 description 1
- 108010009413 Pyrophosphatases Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010054184 Small intestine carcinoma Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 238000010459 TALEN Methods 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 206010062129 Tongue neoplasm Diseases 0.000 description 1
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000012152 bradford reagent Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 201000000312 duodenum cancer Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 208000022013 kidney Wilms tumor Diseases 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007762 localization of cell Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000011242 molecular targeted therapy Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000001293 nucleolytic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 208000037922 refractory disease Diseases 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 102200085789 rs121913279 Human genes 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 201000006134 tongue cancer Diseases 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/06—Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
- C08G73/0605—Polycondensates containing five-membered rings, not condensed with other rings, with nitrogen atoms as the only ring hetero atoms
- C08G73/0611—Polycondensates containing five-membered rings, not condensed with other rings, with nitrogen atoms as the only ring hetero atoms with only one nitrogen atom in the ring, e.g. polypyrroles
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/06—Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
- C08G73/0605—Polycondensates containing five-membered rings, not condensed with other rings, with nitrogen atoms as the only ring hetero atoms
- C08G73/0616—Polycondensates containing five-membered rings, not condensed with other rings, with nitrogen atoms as the only ring hetero atoms with only two nitrogen atoms in the ring
Definitions
- the present invention relates to a novel alkylating agent that alkylates a gene mutation site of a driver oncogene as a target.
- driver oncogene essential proto-oncogenes
- Driver oncogene is a proto-oncogene that has mutations specifically in cancer cells (point mutations, small deletions, insertions or translocations, amplifications, etc.), and has gene mutations that are thought to cause cancer. It is a gene. Therefore, it has been demonstrated that targeting a driver oncogene and developing a drug that suppresses its function is an extremely effective method for developing a specific drug for cancer patients. Examples include Iressa, which shows dramatic efficacy in lung cancer patients with mutant EGFR, trastuzumab effective in breast cancer patients derived from high expression of HER2, and imatinib, an activity inhibitor of fusion protein BCR-ABL.
- the gene mutation of the driver oncogene is (1) gene sequence change (point mutation, chromosomal translocation, deletion or / and insertion).
- (Polymorphism) includes tumors that are monoallelic or homoallelic in tumors) and (2) changes in gene copy number (increased gene expression).
- driver oncogene having the mutation of (1) RAS, KRAS, HRAS, NRAS, BCR-ABL, EGFR, c-KIT, BRAF, PI3K, ALK, PIK3CA, FLT3, MET, BCL2, EML4-ALK, APC, BRCA1 / 2, TP53, MSH2, MLH1, MSH6, PMS2, RB1, PTEN, VHL, P16, MEN1, RET, CDH1, STK11, PTCH, Her2 / neu, EGFR, MYC , MYCN, MET, etc. are known.
- Other driver oncogenes are registered in the oncogene mutation database (COSMIC [Catalogue of somatic mutations in cancer]) and the like.
- Pyrrole / imidazole polyamide is an artificial small molecule developed with the antibiotic destamycin as a motif, and has been reported to bind to the minor groove of double-stranded DNA in a sequence-specific manner. Many studies on gene expression suppression have been reported. In addition, research on drugs for renal disorders, anticancer agents, corneal trauma, hypertrophic scars, bone diseases, etc. are being conducted through animal experiments using mice. In recent years, as part of iPS cell research, research on iPS cell induction by PIP has also been conducted in research on iCeMs, an iPS cell project at Kyoto University. It is a small organic molecule.
- PIP PIP-like protein
- the characteristics of PIP are (1) It is possible to design an arbitrary gene sequence as a target, (2) The binding ability to DNA is stronger than a transcription factor, (3) The cell without a vector or drug delivery system (DDS) Incorporated into the nucleus, (4) Not degraded by nucleolytic enzymes, stable in cells and in vivo, and excreted as undegraded product from urine bile, (5) Easy modification of N and C terminus It is possible to form a complex with various functional small molecules.
- DDS drug delivery system
- PIP recognizes Py / Im pairs as CG, Py / Py pairs as AT or TA, and Im / Py pairs as GCs, which can bind sequence-specifically to various arbitrary double-stranded DNAs. is there. PIP bound to a target gene has been studied as a gene switch that inhibits binding of transcription factors to DNA and suppresses specific gene expression.
- the present inventor synthesized a complex of an alkylated functional group and PIP using a PIP structure with high sequence recognition specificity, and alkylated a specific base sequence of DNA (Patent Document 2), histone
- Patent Document 2 The present inventors have succeeded in synthesizing a complex of a modification control agent and PIP and completing the invention relating to the target gene-specific histone modification control agent (Patent Document 1).
- PIP target gene-specific histone modification control agent
- drugs can be synthesized by targeting driver mutations (genetic mutations that cause cancer) of driver oncogene, and actually have a tumor-suppressing effect. Not.
- an object of the present invention is to provide a novel alkylating agent that alkylates a gene mutation site of a driver oncogene as a target.
- the present inventor designed pyrrole-imidazole polyamide (PIP) that specifically binds to a gene mutation site of a driver oncogene, and binds an alkyl reaction site to the designed PIP. And synthesized a novel compound that specifically recognizes and binds to the gene mutation site of the driver oncogene and alkylates it, and the new compound is also efficiently applied to tumor cells and tumor stem cells. The delivery was confirmed and the present invention was completed.
- PIP pyrrole-imidazole polyamide
- the present invention is as follows. (1) A complex of a DNA binding compound that specifically binds to a gene mutation site of a driver oncogene and an alkylating agent. (2) The complex according to (1), wherein the gene mutation site is a change in gene sequence and / or a change in gene copy number.
- Driver Oncogene is KRAS, HRAS, NRAS, BCR-ABL, EGFR, c-KIT, BRAF, PI3K, ALK, PIK3CA, FLT3, MET, BCL2, EML4-ALK, APC, BRCA1 / 2, TP53, MSH2 , MLH1, MSH6, PMS2, RB1, PTEN, VHL, P16, MEN1, RET, CDH1, STK11, PTCH, Her2 / neu, EGFR, MYC, MYCN, and MET, and genes registered in the cancer gene mutation database
- the complex according to any one of (1) and (2), which is at least one selected from the group consisting of: (4) DNA binding compound is Bridged Nucleic Acid (crosslinked nucleic acid), Locked Nucleic Acid (LNA), PNA, DNA binding protein complex, pyrrole / imidazole polyamide (PIP)), modified pyrrole / imidazole polyamide (PIP) or
- a KRAS gene codon 12 mutant alkylating agent comprising the complex according to (8).
- An ALK gene F1174L mutant alkylating agent comprising the complex according to (9).
- a PIK3CA gene E545K mutant alkylating agent comprising the complex according to any one of (10) and (11).
- a MYCN gene amplified mutant alkylating agent comprising the complex according to any one of (12) and (13).
- a pharmaceutical composition comprising the complex according to any one of (1) to (6) and (8) to (13).
- a kit comprising the complex according to any one of (1) to (6) and (8) to (13).
- a research reagent kit comprising the complex according to any one of (1) to (6) and (8) to (13).
- a therapeutic kit comprising the complex according to any one of (1) to (6) and (8) to (13).
- (23) (1) Designing a DNA binding compound so as to specifically bind to a gene mutation site of a driver oncogene, (2) including a step of binding the designed DNA-binding compound and an alkylating agent; A method for producing a complex in which a gene mutation site of a driver oncogene is specifically alkylated.
- Driver oncogene is RAS, KRAS, HRAS, NRAS, BCR-ABL, EGFR, c-KIT, BRAF, PI3K, ALK, PIK3CA, FLT3, MET, BCL2, EML4-ALK, APC, BRCA1 / 2, TP53 , MSH2, MLH1, MSH6, PMS2, RB1, PTEN, VHL, P16, MEN1, RET, CDH1, STK11, PTCH, Her2 / neu, EGFR, MYC, MYCN and MET, and genes registered in the cancer gene mutation database
- the DNA-binding compound is Bridged Nucleic Acid (cross-linked nucleic acid), Locked Nucleic Acid (LNA), PNA, DNA-binding protein complex, pyrrole / imidazole polyamide (PIP)), pyrrole / imidazole
- the present invention provides a complex for specifically alkylating cancer cells having a driver oncogene gene mutation.
- the complex of the present invention can be used as a pharmaceutical composition or an anticancer agent.
- the complex of the present invention is a compound (KR12) that specifically alkylates the codon 12 mutation of the KRAS gene.
- the compound (MYCNA1, MYCNA2, MYCNA3) specifically alkylates the MYCN gene having an increased genome copy number.
- the complex of the present invention is ALK-FL-1, which targets the ALK gene mutation (F1174L), and P3A-E5K-, which targets the PIK3CA gene mutation (E545K). 1, P3A-E5K-2.
- the methodology of adding a polyamide that specifically binds a driver oncogene gene mutation to an alkylating agent is one of the most effective approaches for creating new anticancer agents that recognize various tumor-specific mutations. It became clear that there was. Specifically, CBI, which is an alkylating agent, is added to PIP, which is an organic small molecule that specifically binds to a base sequence, and has a strong binding force to DNA and effectively suppresses gene expression even in small amounts. It became clear to develop a therapeutic drug for mutation driver oncogene. This effect is thought to be due to the fact that DNA damage caused by alkylation induces cell death signals and suppresses oncogenes that suppress them, thereby inducing cell death including cancer cells that do not normally cause cell death. .
- the present invention provides a technique for delivering an alkylating agent to a specific genomic sequence.
- this technique is applied, not only the KRAS oncogene but also various driver oncogenes having cancer-specific mutations are provided.
- it is possible to design and synthesize therapeutic agents that can specifically recognize mutant sequences one after another.
- the same idea as the antibody-drug complex (ADC) technology can be applied, and since it is easy to synthesize, it can be applied to a wide range of applications.
- ADC antibody-drug complex
- KR12 which is a complex of the present invention, exhibits strong anticancer activity specifically against cancer cells having a mutated RAS driver oncogene at a low concentration (resulting in cell growth suppression from picomolar), and can be automatically synthesized. It has excellent effects such as high accumulation and accumulation in tumors, localization in the nucleus, and no side effects such as weight loss. Therefore, KR12, which is the complex of the present invention, not only provides a therapeutic agent for cancer having a RAS gene mutation, which is a clinical problem, but also targets a RAS gene mutation that is difficult to develop. This will enable the development of new and innovative therapeutic drugs.
- KR12 which is the complex of the present invention, is expected to promote development research (physical property testing, safety testing, pharmacokinetics, mass synthesis with GMP) toward the start of clinical trials. Further, if the method of the present invention is applied, it is possible to develop a further innovative therapeutic agent that exhibits the same effect as KR12.
- KR12 was synthesized, and the induction of cell death was compared between a cancer cell line having a mutation that can recognize KR12 at codon 12 and a cancer cell line having no mutation that could recognize KR12 at codon 12.
- a cancer cell line having a mutation capable of recognizing KR12 of codon 12 at a low concentration was induced to cell death.
- the mutant KRAS gene that can be recognized by KR12 at codon 12 was specifically transcriptionally suppressed.
- KR12 is a target oncogene because of its ability to induce cell death and to confirm the growth-inhibiting effect of KR12 administration specifically in tumors having mutations that can be recognized by KR12 in human colon cancer transplanted into mice. It has been found that it is an anticancer agent capable of suppressing driver mutation and obtaining anticancer properties.
- ALK-FL-1 which targets the ALK gene mutation (F1174L) against a cancer cell line having an ALK gene mutation (F1174L) and a PIK3CA gene mutation (E545K) known as a driver oncogene mutation
- ALK-FL-1 which targets the ALK gene mutation (F1174L) against a cancer cell line having an ALK gene mutation (F1174L) and a PIK3CA gene mutation (E545K) known as a driver oncogene mutation
- MYCN alkylated PIPs (MYCNA1, MYCNA2, MYCNA3) were synthesized that were frequently amplified in tumors and the like and targeted to MYCN, which is a poor prognosis factor.
- MYCNA1, MYCNA2, and MYCNA3 suppressed the proliferation of neuroblastoma cells in which the MYCN gene was amplified.
- MYCNA3 suppressed cell growth more effectively in cells with strong MYCN gene amplification, and was less effective in normal cells and other cancer cells.
- Driver oncogene (essential proto-oncogene) is thought to cause mutations (point mutations, small deletions, insertions or translocations, amplifications, etc.) specifically in cancer cells, leading to canceration mainly. It is a proto-oncogene having a gene mutation. Deletion and translocation mutations include mutations in which SNPs (single nucleotide polymorphisms) that are heteroalleles in normal cells become monoallelic or homoallelic in tumors.
- the driver oncogene of the present invention includes those registered in a cancer gene mutation database.
- the cancer gene mutation database is COSMIC ([Catalogue of somatic mutations in cancer]), and other databases are also included.
- Mutations of driver oncogenes are: (1) gene sequence changes (point mutations, chromosomal translocations, deletions and / or insertions, and deletions and translocation mutations in SNPs (single nucleotide polymorphisms) that are heteroallelic in normal cells ) Also includes mutations that become monoallelic or homoallelic in tumors) and (2) changes in gene copy number (increased gene expression).
- KRAS As the driver oncogene having the mutation (1), KRAS, HRAS, NRAS, BCR-ABL, EGFR, c-KIT, BRAF, PI3K, ALK, PIK3CA, FLT3, MET, BCL2, EML4-ALK, APC, BRCA1 / 2, TP53, MSH2, MLH1, MSH6, PMS2, RB1, PTEN, VHL, P16, MEN1, RET, CDH1, STK11, PTCH, etc., and those having the mutation (2), Her2 / neu, EGFR , MYC, MYCN, MET and the like.
- the RAS gene is a proto-oncogene belonging to the driver oncogene and encodes a membrane-bound p21-ras protein of about 21 kDa.
- the p21-ras protein is a low molecular weight guanyl pyrophosphatase (GTPase) that circulates between activated (RAS-GTP) and inactive (RAS-GDP).
- GTPase guanyl pyrophosphatase
- the p21-ras protein is converted to an activated form by a guanine nucleotide exchange factor (GEF) and converted to an inactive form by a GTPase activating protein (GAP).
- GEF guanine nucleotide exchange factor
- GAP GTPase activating protein
- the RAS gene controls the activity of signal transduction pathways related to cell growth and differentiation such as the MAP kinase pathway and PI3 kinase pathway.
- the RAS gene family is widely conserved among animal species.
- the RAS gene family is a proto-oncogene, and the mutated RAS gene family is found in various cancers and has been found in 20-30% of human cancer tumors.
- mutations in the KRAS gene are the most common gene mutations found in human cancer tumors. Mutations in the KRAS gene are frequently identified in pancreatic cancer, colorectal cancer, thyroid cancer, lung cancer, head and neck cancer, and endometrial cancer, and precancerous conditions such as myelodysplastic syndrome, thyroid and colon adenoma But it has been identified.
- mutations in the KRAS gene are observed in about 35 to 40% of colorectal cancers and about 90% of pancreatic cancers.
- the codon 12 mutation KRAS gene, KRAS gene (accession number: NM_033360.2) exon 2 of the codon 12 (wild type GGT, amino acids Gly) of G C T of (Ala), G A T ( Asp), C It is a single base substitution mutation of GT (Arg), T GT (Cys), A GT (Ser), or G T T (Val).
- a mutation occurs in codon 12 of the KRAS gene, a point mutation is present in the P-loop of the p21-ras protein, and the constitutively activated p21-ras protein is expressed.
- FIG. 1 shows a single base substitution mutation from GGT (Gly) to G A T (Asp).
- the MYCN gene is a proto-oncogene belonging to the driver oncogene, and MYCN amplification is observed in 4 to 8% of early cases of neuroblastoma and about 30% of advanced cases. It has been. It is known that MYCN amplification is strongly associated with rapid tumor progression and malignancy. At present, the presence or absence of MYCN amplification is an essential test item in treatment protocols based on neuroblastoma risk classification. It has become.
- FIG. 2 shows the amplified portion of the MYCN gene.
- Driver oncogene gene mutation recognition polyamide which is a component of the complex, is a polyamide designed to recognize driver oncogene mutation. “Recognize driver oncogene mutation” means that the driver oncogene mutation-recognizing polyamide binds to the driver oncogene mutation base sequence and / or the vicinity thereof (for example, bonding by hydrogen bonding or cross-linking). Means.
- Driver oncogene mutation recognition compounds include pyrrole / imidazole polyamide (PIP) (cyclic, hairpin structure, PIP compound including tandem type connecting hairpin structures), Peptide Nucleic Acid (PNA), and Bridged Nucleic Acid (crosslinked nucleic acid).
- DNA binding compounds such as DNA binding proteins such as Locked Nucleic Acid (LNA) and zinc fingers, chimeric proteins thereof, DNA binding protein complexes and complexes such as guide RNA protein complexes.
- LNA Locked Nucleic Acid
- a modified PIP modified to maintain or improve the binding ability to DNA is also included.
- the modified PIP include a modified product obtained by adding an amine to the ⁇ -position or ⁇ -position of ⁇ -aminobutyric acid of PIP, N- ⁇ -N- ⁇ -aminobutyric acid, and N- ⁇ -N- ⁇ -aminobutyric acid.
- a modified product having a substituted side chain a modified product obtained by modifying the modified product with a molecule such as FITC or biotin, a modified product obtained by modifying the N-terminus of PIP with a molecule such as FITC or biotin, and the C-terminus having isophthalic acid, etc.
- Modification products modified with the above molecule may be mentioned.
- the pyrrole-imidazole polyamide is a polyamide containing an N-methylpyrrole unit (Py), an N-methylimidazole unit (Im), and a ⁇ -aminobutyric acid part. What are Py, Im, and ⁇ -aminobutyric acid part? They are linked to each other by an amide bond (—C ( ⁇ O) —NH—) (Trauger et al, Nature, 382, 559-61 (1996); White et al, Chem. Biol., 4, 569-78 (1997). And Dervan, Bioorg. Med. Chem., 9, 2215-35 (2001)).
- PIP takes a U-shaped conformation (hairpin type) by folding the entire ⁇ -aminobutyric acid moiety as a linker ( ⁇ -linker).
- ⁇ -linker linker
- two chains containing Py and Im are arranged in parallel across the linker.
- a specific base pair in DNA when the Py and Im pair between the two strands is a specific combination (Py / Im pair, Im / Py pair, Py / Py pair, or Im / Im pair) can be bound with high affinity.
- a Py / Im pair can bind to a CG base pair
- an Im / Py pair can bind to a GC base pair.
- Py / Py pairs can bind to both AT base pairs and TA base pairs (White et al, Chem. Biol., 4, 569-78 (1997); Dervan: Bioorg. Med). Chem., 9, 2215-35 (2001)).
- PIP may contain 3-hydroxypyrrole (Hp) or ⁇ -alanine.
- Hp 3-hydroxypyrrole
- the Hp / Py pair can bind to a TA base pair (White at al, Nature, 391, 468-71 (1998)).
- the ⁇ -linker has side chains such as N- ⁇ -N- ⁇ -aminobutyric acid and N- ⁇ -N- ⁇ -aminobutyric acid having amino groups, and these are molecules such as FITC and biotin. It may be modified.
- N-terminal of PIP may be modified not only with an acetyl group but also with a molecule such as FITC or biotin.
- ⁇ -Alanine / ⁇ -alanine can be bound to a TA base pair or an AT base pair. Therefore, a PIP that recognizes the regulatory region of the target gene can be designed by changing the combination of Py and Im pairs according to the target DNA sequence.
- a PIP design method and manufacturing method are known (for example, Japanese Patent No. 3045706, Japanese Patent Application Laid-Open No. 2001-136974, and WO 03/000683).
- PIP can recognize the gene sequence, for example, a pair of imidazole and pyrrole that recognize guanine and cytosine in order to recognize mutations G12D and G12V of the KRAS driver oncogene gene in which GGT shown in FIG. 1 is changed to GAT or GTT.
- the polyamide was designed using a pair of pyrrole and ⁇ -alanine that recognizes adenine and thymine.
- an indole group between the pyrrole group and secoCBI it was decided to synthesize so that a good angle could be obtained due to the proximity of the alkylation site to N3 of adenine for structural analysis.
- KR12 was designed in consideration of the occurrence of alkylation in the KRAS transcription template DNA. As shown in FIG. 7, KR12 was synthesized as a compound that recognizes G12D mutation 5'-ACGCCATCA-3 'and G12V mutation 5'-ACGCCAACA-3' and alkylates N3 of 3 'adenine.
- SNP single nucleotide polymorphism
- SNP single nucleotide polymorphism
- Bridged Nucleic Acid cross-linked nucleic acid
- Locked Nucleic Acid LNA
- Bridged Nucleic Acid cross-linked nucleic acid
- LNA Locked Nucleic Acid
- 2 ′, 4′-BNA or 2 ′, 4′-ENA Ethylene-Bridged Nucleic Acids in which the 2 ′ oxygen atom and the 4 ′ carbon atom of RNA are bridged by an ethylene chain can be synthesized.
- LNA is also available from Proligo.
- the alkylating agent includes a compound having a functional group that alkylates DNA. Any alkylating agent may be used as long as it contains a compound having both an alkylating ability and a sequence recognizing ability with respect to a specific base sequence present in DNA, and is not particularly limited. For example, a compound containing a functional group described in WO2010 / 001933 can be used.
- the alkylating agent introduces an alkyl group into the guanine N-7 position or adenine N-3 position of DNA, and causes an adduct formation or a cross-linking reaction between guanines or adenines.
- Double-stranded DNA that has undergone a cross-linking reaction or double-stranded DNA that has been formed as an adduct is difficult to repair by the repair mechanism. As a result, DNA cannot be transcribed or replicated, resulting in cell growth arrest or cell death due to apoptosis. Will be induced.
- DNA binding proteins include binding proteins such as zinc fingers, chimeric proteins such as TALEN (TALE Nuclease), and complex proteins such as Crisper using guide nucleic acids (CRISPR).
- secoCBI (1-chloromethyl-5-hydroxy-1,2-dihydro-3H-benzo [e] indole) is a compound represented by the following formula 3.
- secoCBI is one of the known compounds that alkylate DNA.
- secoCBI can be synthesized by methods described in known literature ((a) Boger, DL; Yun, WY; Teegarden, BRJ Org. Chem. 1992, 57, 2873.
- the composite of the present invention can be synthesized by bonding the polyamide and the alkylating agent.
- the synthesis method can be carried out by a known method (J. Am. Chem. SOC. 1995, 117, 2479-2490).
- “Binding” may be direct or via a linker.
- the linker is not particularly limited as long as it does not interfere with the action of the alkylating agent and does not prevent recognition of the gene mutation site of the driver oncogene. For example, an amide bond, phosphodisulfide bond, ester bond, coordination bond, An ether bond etc. can be illustrated.
- the alkylating agent containing the complex of the present invention may contain a carrier or an additive in addition to the complex of the present invention depending on the purpose of use.
- Such carriers and additives include water, acetic acid, organic solvents, collagen, polyvinyl alcohol, polyvinylpyrrolidone, carboxyvinyl polymer, sodium carboxymethylcellulose, sodium polyacrylate, sodium alginate, water-soluble dextran, sodium carboxymethyl starch, pectin , Methylcellulose, ethylcellulose, xanthan gum, gum arabic, casein, agar, polyethylene glycol, diglycerin, glycerin, propylene glycol, petrolatum, paraffin, stearyl alcohol, stearic acid, human serum albumin, mannitol, sorbitol, lactose, surfactant, etc. Can be mentioned.
- complex of this invention can be suitably adjusted according to a use purpose.
- the pharmaceutical composition of the present invention is a composition comprising the complex.
- Various diseases can be treated and prevented by administering the pharmaceutical composition in vivo.
- the pharmaceutical composition of the present invention targets all organisms that use double-stranded DNA for biological control, particularly mammals (eg, humans, rats, rabbits, sheep, pigs, cows, cats, dogs, monkeys, etc.). can do.
- the target diseases of the pharmaceutical composition of the present invention include diseases with gene mutations such as cancer, neurological / psychiatric diseases, lifestyle-related diseases, sleep disorders, dermatology, ophthalmology, or diseases with strong local symptoms in the otolaryngological region.
- Examples include infectious diseases, allergic diseases, diseases involving cellular aging, thyroid hormone refractory disease, aging, cystic fibrosis, and gastrointestinal diseases.
- examples of cancer include brain tumor, cervical cancer, esophageal cancer, tongue cancer, lung cancer, breast cancer, pancreatic cancer, gastric cancer, small intestine or duodenal cancer, colon cancer (colon cancer, rectal cancer), bladder cancer, renal cancer.
- sarcoma eg, osteosarcoma, chondrosarcoma, Kaposi's sarcom
- the lifestyle-related diseases are not particularly limited, and examples thereof include hypertension and diabetes.
- diseases and infectious diseases having strong local symptoms in the dermatology, ophthalmology, or otolaryngological region include psoriasis, chronic dermatitis, sinusitis, glaucoma, retinal degeneration, and the like.
- allergic diseases include atopic dermatitis and hay fever.
- diseases involving cell aging include skin wrinkles, sagging, and pigmentation.
- neurological / psychiatric disorders include so, depression, schizophrenia, autism, bipolar disorder, Alzheimer's disease, sleep disorder, dementia and the like.
- Preferred target diseases of the pharmaceutical composition of the present invention include all diseases derived from mutations in driver oncogene. All diseases derived from codon 12 mutation of KRAS gene, amplification of MYCN gene, mutation of ALK gene (F1174L), mutation of PIK3CA gene (E545K) are also included. For example, colon cancer, pancreatic cancer, colorectal cancer, thyroid cancer, lung cancer, head and neck cancer, endometrial cancer, myelodysplastic syndrome, thyroid and colon adenoma, neuroblastoma and the like.
- the pharmaceutical composition of the present invention acts more effectively on cells having a driver oncogene mutation rather than normal cells, promotes DNA cross-linking by alkylation, induces cell death mechanisms due to DNA damage, By suppressing the expression of the driver oncogene and inhibiting cell proliferation, the disease-causing cells can be killed, and the disease can be treated and prevented.
- the pharmaceutical composition of the present invention may be in any dosage form for oral administration and parenteral administration.
- dosage forms can be formulated according to conventional methods, and may contain pharmaceutically acceptable carriers and additives.
- Such carriers and additives include water, acetic acid, pharmaceutically acceptable organic solvents, collagen, polyvinyl alcohol, polyvinyl pyrrolidone, carboxyvinyl polymer, sodium carboxymethylcellulose, sodium polyacrylate, sodium alginate, water-soluble dextran, Sodium carboxymethyl starch, pectin, methylcellulose, ethylcellulose, xanthan gum, gum arabic, casein, agar, polyethylene glycol, diglycerin, glycerin, propylene glycol, petrolatum, paraffin, stearyl alcohol, stearic acid, human serum albumin, mannitol, sorbitol, lactose And surfactants acceptable as pharmaceutical additives.
- the additive is selected from the above alone or in combination as appropriate depending on the dosage form of the pharmaceutical composition of the present invention.
- oral administration tablets, capsules, fine granules, powders, granules, solutions, syrups, sprays, coatings, eye drops, external preparations, etc. or appropriate dosage forms for oral administration Can be administered.
- parenteral administration examples include an injection form.
- injection form it can be administered systemically or locally by intravenous injection such as infusion, subcutaneous injection, intraperitoneal injection, intratumoral injection, and the like.
- the pharmaceutical composition of the present invention when used as an injectable preparation, is dissolved in a solvent (eg, physiological saline, buffer solution, glucose solution, 0.1% acetic acid, etc.) and an appropriate additive (human serum) Albumin, PEG, mannose-modified dendrimer, cyclodextrin conjugate, etc.) can be used.
- a solvent eg, physiological saline, buffer solution, glucose solution, 0.1% acetic acid, etc.
- an appropriate additive human serum
- Albumin human serum
- PEG mannose-modified dendrimer
- cyclodextrin conjugate etc.
- it may be freeze-dried to obtain a dosage form that dissolves before use.
- the freeze-drying excipient for example, sugar alcohols and saccharides such as mannitol and glucose can be used.
- the dosage of the pharmaceutical composition of the present invention or the compound of the present invention varies depending on age, sex, symptom, route of administration, frequency of administration, and dosage form.
- the dosage is 0.01 to 1000 mg per day, preferably 0.1 to 100 mg, more preferably 1 to 30 mg.
- the administration method is appropriately selected depending on the age and symptoms of the patient. Administration may be divided, for example, once every several days, once per day, or divided into 2 to 4 times.
- the pharmaceutical composition of the present invention can be used as an anticancer agent.
- the types of cancer to be targeted are, for example, colon cancer, pancreatic cancer, colorectal cancer, thyroid cancer, lung cancer, cervical cancer, endometrial cancer, myelodysplastic syndrome, thyroid and colon adenoma, neuroblastoma, etc.
- the present invention is not limited thereto, and all cancers derived from driver oncogene mutations, all cancers derived from codon 12 mutation of KRAS gene or amplification of MYCN gene are targeted.
- the anticancer agent of the present invention may contain a carrier and a composition according to the purpose of use, like the above-described pharmaceutical composition and alkylating agent.
- the kit of the present invention contains pharmaceutically acceptable carriers and additives, reagents, adjuvants, dedicated containers, other necessary accessories, instructions and the like in addition to the compound of the present invention.
- the kit of the present invention can also be used as a cancer treatment kit and a research reagent kit.
- codon 12 of the KRAS gene is obtained by condensing secoCBI that specifically alkylates the adenine on the minor groove side of the DNA base to a hairpin type PIP (hPIP) that targets the mutated sequence of codon 12 of the KRAS gene.
- hPIP hairpin type PIP
- HPIP-secoCBI KR12
- KR12 has sufficient ability to suppress tumor growth at a low concentration against colorectal cancer cells having the KRAS gene codon 12 mutation, and subcutaneously transplants LS180 cells (derived from colorectal cancer) in which the KRAS gene codon 12 mutation is heterozygous.
- SW480 cells derived from colorectal cancer
- KR12 did not show an inhibitory effect on HT29 cells (derived from colon cancer) in which the KRAS gene was wild type. From these results, it was revealed that KR12 exhibits a tumor growth inhibitory effect in vitro and in vivo against cancer cells having the KRAS gene codon 12 mutation.
- KR12 specifically alkylates the nucleotide sequence of codon 12 mutation of KRAS gene, selectively inhibits the expression of KRAS gene having codon 12 mutation, and cancer cells caused by codon 12 mutation of KRAS gene It has been found that there is an effect of specifically suppressing the growth of the. This result suggests that the methodology of adding PIP to the alkylation reaction site is one of the most effective approaches for creating new anticancer agents that recognize various tumor-specific mutations.
- codon 12 mutant alkylated PIP (KR12) of KRAS gene The chemical structure of codon 12 mutant alkylated PIP (KR12) of KRAS gene is represented by the following chemical formula 14.
- the method for producing the compound of the present invention is as follows. PIP having a carboxylic acid end was dissolved in 100 ⁇ L of DMF, and iPr2NEt (0.5 ⁇ L, 2.86 ⁇ mol) and PyBOP (1.0 mg, 1.95 ⁇ mol) were added. After reacting the reaction solution at room temperature for 2 hours with stirring, it was confirmed by HPLC whether or not an active form of 1-hydroxybenzotriazole ester was formed.
- the target transformed white colonies were 500 nM primer set (T7: 5′-TAATACGACTCACTATAGG-3 ′ (SEQ ID NO: 3), sp6: 5′-CATACGATTTAGGTGACACTATAG-3 ′ (SEQ ID NO: 4)) and 1U GoTaq from Promega. (R) Identified by colony direct PCR using a 10 ⁇ L reaction solution containing Green Master Mix. The amplification cycle was performed as follows. After incubating the reaction solution at 95 ° C. for 2 minutes, the reaction was repeated 30 times at 95 ° C. for 30 seconds, 55 ° C. for 30 seconds, and 72 ° C.
- FIG. 7A shows the results of using K480 mutant sequences of SW480 cells (colon cancer) and FIG. 7B of AsPC-1 cells (pancreatic cancer).
- KR12 specifically induced a concentration-dependent alkylation of the codon 12 mutant sequence of the KRAS gene in SW480 cells (G12V) and AsPC-1 cells (G12D).
- Cytotoxicity test for colon cancer cell LS180 and measurement of 50% inhibitory concentration (IC50) Using LS180 colon cell line, cells were seeded per well of 96-well microplate so as to be 3000 to 5000 cells / well, Cultured overnight. The next day, KR12 recognizing codon 12 mutation, WT recognizing wild-type KRAS, and C12-Dp having the same structure as KR12 to which no alkylating agent is added are 1 nM, 10 nM, 30 nM, 100 nM, 300 nM, 1 ⁇ M Each concentration was added to the cells and treated for 48 hours. Then, using cell counting kit-8 (DOJINDO), WST-8 reagent was added per well and allowed to react for 2 hours.
- DOJINDO cell counting kit-8
- IC50 10 (LOG (A / B) ⁇ (50-C) / (DC) + LOG (B)), A: high concentration sandwiching 50%, B: low concentration sandwiching 50% , C: inhibition rate with B, D: inhibition rate with A were used.
- Cytotoxicity test for various cancer cells and measurement of 50% inhibitory concentration (IC50) Using colon cancer and pancreatic cancer cell lines, each well of a 96-well microplate was adjusted to 3000 to 5000 cells / well. Cells were seeded and cultured overnight. The next day, each cell was treated for 48 hours with KR12 which recognizes the codon 12 mutation at concentrations of 1 nM, 10 nM, 30 nM, 100 nM, 300 nM, 1 ⁇ M. Then, using cell counting kit-8, WST-8 reagent was added per well and reacted for 2 hours, and then the number of cells was measured by colorimetric analysis at a wavelength of 450 nm with a microplate reader.
- IC50 50% inhibitory concentration
- the number of cells is calculated by 1) calculating the average value of only the medium, 2) subtracting the average value of medium from each well, 3) calculating the average value of DMSO, and 4) calculating the average value of DMSO by subtracting the medium. Divided by x100, 5) The average value and standard deviation of each treatment section were calculated, and a graph was prepared.
- the cells used in the experiments are SW480, SW620, SNU-C2B, LS180, SW1463, DLD-1, HT29, and Caco-2 human cancer cell lines (purchased from European Collection of Cell Cultures (ECACC)).
- the experimental results are shown in Table 1.
- IC50 for KR12, SW480, SW620, SNU-C2B, LS180, and HCT116 showed low values, and SW1463, DLD-1, HT29, and Caco-2 showed high values. That is, in the cell line having the mutation of codon 12 recognized by KR12, IC50 showed a low value of 100 nM or less.
- SW1463, DLD-1, HT-29, and Caco-2 are cell lines that do not have the mutation of codon 12 recognized by KR12, and their IC50s showed values of 100 nM or more.
- FIG. 9 shows a graph of the concentration-dependent cell growth inhibitory effects of HT29, Caco2, and SW1463 that do not have the mutation of codon 12 recognized by KR12, and SW480, SW620, and LS180 that have the mutation.
- LS180 was treated with 50 nM (dissolved in 0.125% DMSO) KR12 and KR13 for 72 hours and a long-term treatment experiment was conducted for 14 days.
- the control was cultured for 14 days in a MEM medium containing 10% FBS and 0.125% DMSO.
- FIG. 10A The experimental results are shown in FIG. 10A.
- Treatment with 50 nM KR12 increased S phase cells of LS180, and prolonged administration of KR12 significantly increased SubG1 phase cells.
- the S phase and G2M phase indicate cell cycle arrest, and the SubG1 phase indicates cell death.
- KR12 was found to lead LS180 cells from cell cycle arrest to cell death with increasing concentrations.
- treatment with KR13 that does not recognize the codon 12 mutation slightly increased S-phase cells and G2M, but the increase in SubG1 phase was not significant even with long-term administration.
- the cells were collected, stirred in 50 ⁇ l of PBS solution, 3 ⁇ l of 1.5% Triton X (in water) and 3 ⁇ l of RNase (1 mg / ml in water) were added at 37 ° C. for 30 minutes. Treatment for 3 minutes, then add 3 ⁇ l proteinase K (1 mg / ml) for 30 minutes at 37 ° C, add 12 ⁇ l of 6xloading buffer, treat for 10 minutes at 65 ° C and immediately 20 ⁇ l with 2% agarose gel in TBE. The solution was electrophoresed at 100 V and stained with ethidium.
- the amount of protein was determined by Bradford reagent (Bio-Rad, CA), migrated by 10% SDS-PAGE, transferred to polyvinylidene fluoride membranes (Millipore, MA), 5% dry milk using Tris-buffered saline (TBS) plus 0.1% Tween 20 as a blocking agent, anti- ⁇ H2AX (2F3, BioLegend, CA), anti-p53 (D O-1, Santa Cruz Biotechnology, CA), anti-PARP (Cell Signaling Technologies, MA), or anti-actin antibody (20-33, Sigma, MO), respectively, and further HRP-conjugated anti-IgG -Treated with rabbit IgG (Cell Signaling Technologies, MA). Before the secondary antibody treatment, the primary antibody was appropriately washed. Thereafter, it was washed with TBS plus 0.1% Tween 20, and the protein was identified by ECL chemiluminescence (Amersham Biosciences, NJ).
- RT-PCR HT29 and LS180 were cultured in 12-well plates. The next day, the cells were treated with 50 nM KR12 and KR13, and then cultured for 48 hours. The cells were collected and RNA was extracted. RNeasy mini kit (Qiagen, CA) RT-PCR was used for the extraction. Next, using the extracted RNA as a template, cDNA for reverse transcription was prepared according to Super Script VILO cDNA Synthesis Kit (Invitrogen, CA). Using the cDNA as a template, PCR was performed at 94 ° C. for 5 minutes, followed by 20 cycles of 94 ° C. for 30 seconds, 55 ° C. for 30 seconds, 72 ° C.
- the PCR product was subjected to electrophoretic analysis on a 2% agarose gel. The amount of PCR product was calculated from a photograph stained with ethidium bromide. The following primer sets were used for PCR.
- the forward primer (sense) and reverse primer (antisense) that simultaneously amplify the mutant gene and the wild type, and the forward primer (sense) and reverse primer (antisense) of the RPS18 (ribosomal protein S18) gene as internal standards are shown below.
- the following primer set M13-F1 primer and M13-R1 primer were used for amplification.
- the sequence of the amplified DNA was decoded with a sequencer using the sequencing primer KRAS-2R, and the KRAS gene mutation site of each colony was identified.
- M13-F1 primer M13-R1 primer:
- RAS activity measurement The number of cells on 2 ⁇ 10 6 cells / 100 mm plate or 1 ⁇ 10 6 cells / 100 mm plate was cultured in complete nutrient medium, and the next day, cells were treated with 50 nM KR12, KR13 and cultured for 48 hours, Cells were lysed in magnesium lysis buffer (MLB) and RAS activity levels were measured using RAS activation assay kit (Millipore, Mass.).
- MLB magnesium lysis buffer
- HT29 (2 ⁇ 10 6 cells / 100 ⁇ l PBS transplanted subcutaneously, KRAS codon 12 wild type cell line without codon 12 mutation)
- SW480 KRAS-MUTomo: (cell line having 5 ⁇ 10 6 cells / 100 ⁇ l PBS subcutaneously and homozygous for KRAS gene codon 12 mutation G12V)
- LS180 KRAS-MUThetero: (cell line having 3 ⁇ 10 6 cells / 100 ⁇ l PBS subcutaneously and heterozygous for KRAS gene codon 12 mutation G12D)
- HT29 cells having no codon 12 mutation could not suppress tumor growth by administration of KR12 (FIG. 14A), but SW480 cells having codon 12 mutation homozygous were transplanted.
- administration of KR12 significantly reduced tumor size (FIG. 14C).
- Nude mice transplanted with LS180 cells heterozygous for the mutant allele of KR12 and the wild type also showed significant suppression of tumor growth by administration of KR12 (FIG. 14B).
- DMSO / PBS control was administered to nude mice transplanted with SW480 cells, the tumor size only expanded, whereas when KR12 was administered, the tumor size decreased significantly after 2 months. The tumor became very small and hard after 3 months (FIGS. 14A-C, photographs taken at autopsy (after 3 months or when the tumor became more than 2 cm in diameter)).
- FIG. 15 shows the result of an experiment conducted by the same method as in 11 above.
- KR12 showed significantly higher cancer tumor suppression effect than nude mice transplanted with SW480 cells than when KR13 was administered.
- the weight loss tendency observed in seco-CBI was not observed in KR12 and KR13.
- KR12 recognized tumor growth inhibition not exhibited by KR13 that does not recognize the G12D mutant sequence, and did not cause side effects such as weight loss or abnormal health.
- Nude mice administered with KR12 also did not show hair handstand, decreased food intake, decreased exercise, abnormal behavior, or the like.
- ⁇ -alanine was introduced into the N-terminus of C12DP, followed by FITC coupling.
- FITC coupling was performed by passing a 4-fold excess of fluorescein (0.40 mmol), DIEA, and HCTU dissolved in DMF through a column and shaking for 60 minutes.
- LS180 cells were cultured in MEM (gibco) + 10% FBS (gibco) +100 units / ml Penicillin + 100 g / ml Streptmycin (gibco) culture medium, added with FITC-labeled KR12 (1 ⁇ Mol) in a state of about 50% confluence. After time, it was encapsulated (VECTOR VECTASHIELD), stained with DAPI, and observed with a confocal microscope (Leica TCS-SPE).
- KR12 reaches the nucleus of cancer stem cells, it is unlikely to be affected by the mechanism of drug excretion due to the mechanism of drug resistance and may be effective for cancer stem cell therapy. It is considered that KR12 moves into the nucleus because it has a property of being easily taken into the cell from the fat-soluble portion of the PIP structure, quickly moving into the nucleus from the cytoplasm, and binding to DNA. Therefore, it is shown that the complex used in the present invention does not require DDS, which is a drug delivery technique, due to the function of PIP, and PDS itself delivers various small molecule compounds to a specific genome. It is to support becoming.
- mice purchased at 4 weeks of age were transplanted subcutaneously with 5 ⁇ 10 6 SW480 cells at 5 weeks of age, and then FITC-labeled KR12 when the tumor reached 15 mm in diameter. (10 nmol dissolved in 1.25% DMSO (200 ⁇ l)) or FITC (1 mg / kg dissolved in 1.25% DMSO (200 ⁇ l)), 1.25% DMSO was administered from 200 ⁇ l tail vein, and an in vivo imaging system ( NIPPON ROPER: Lumazone FA) was photographed from 0 hour to 10 hours every 2 hours, and the fluorescence level and the individual mouse were also photographed 3 days after 1 day (FIG. 18).
- NIPPON ROPER Lumazone FA
- mouth which performed the same process was dissected 24 hours afterward, each organ and tumor were taken out, and it image
- 1 mg / kg FITC-labeled KR12 (dissolved in 1.25% DMSO (200 ⁇ l)) and 1.25% DMSO were administered from 200 ⁇ l tail vein to subcutaneous mice transplanted with human colon cancer.
- a frozen 10-micron section was prepared with LEICA CM1510S and observed with a confocal microscope (Leica TCS-SPE) (Fig. 20).
- NK12 (10 nMol) fluorescently labeled with FITC was intravenously administered to nude mice transplanted with SW480 cells, and then observed over time with a fluorescent image.
- KR12 was distributed throughout the body and remained accumulated in the tumor, and the liver It showed tumor accumulation property that was gradually discharged from the kidney (FIG. 18).
- it accumulated over time from the whole body after intravenous injection to the tumor, and fluorescence was observed in the tumor 3 days after administration. Then, 24 hours after administration, mice were dissected and the FITC uptake of each organ was observed.
- the specific tumor accumulation property of KR12 is considered to be due to the fact that the lipid-soluble portion of PIP possessed by KR12 promoted uptake of KR12 into cancer cells and prevented KR12 from being excreted from the tumor. It is done. Even in normal cells, KR12 accumulates in the liver and kidney, but cannot remain in the cells, so it is excreted in bile and urine and excreted from these organs. That is, KR12 has an excellent effect of being rapidly excreted from normal cells and staying for a long time against cancer cells.
- the ALK gene is a driver oncogene gene that forms a fusion gene that causes lung cancer and has a point mutation that is constitutively activated in neuroblastoma and promotes canceration. Although it is known that ALK inhibitors are effective for cancer cells having a mutation in the ALK gene, in many cases, cancer cells become resistant to ALK inhibitors and often relapse.
- ALK gene mutation F1174L (3522C> A) in neuroblastoma is recognized in neuroblastoma cells SK-N-SH, SMS-SAN, KELLY, and LAN-1. Therefore, a 10-base-recognized PIP-indole-secoCBI compound ALK-FL-1 that specifically recognizes this mutant sequence was synthesized in the same manner as the synthesis of KR12 (FIG. 21).
- alkylated PIP (ALK-FL-1) of ALK gene
- the chemical structure of alkylated PIP (ALK-FL-1) of ALK gene is represented by the following chemical formula (FIG. 22).
- the method for producing the compound of the present invention is as follows.
- the F1174L (3522C> A) mutation is a PIP-indole-secoCBI that recognizes 10 bases, and a pyrrole that cannot recognize the second guanine from the 3 'side of the wild-type 5'-TGGTGGTTGA-3' sequence is arranged. It was designed as a compound that recognizes 5′-TGGTGGTTTA-3 ′.
- Cytotoxicity tests on neuroblastoma cells and breast cancer cells and measurement experiments of 50% inhibitory concentration (IC50) were performed in the same manner as when KR12 was used.
- the cells used in the experiment were Kelly cells, SK-N-SH cells, IMR-32 cells, SK-N-AS cells, and MDA-MB-231 cells, respectively DMEM, 10% FBS, 1% Pen / St. Culture was performed in a medium, RPMI 1640, 10% FBS, 1% Pen / St medium.
- Each cell was seeded in a 96-well plate at 1000 cells / 50 ⁇ l / well, cultured at 37 ° C., 5% CO 2, under saturated conditions for 24 hours, and then the reagent (final concentration 1, 3, 10, 30, 100 nM) in Medium. After dilution, 50 ⁇ l / well was added and mixed. The cells were again cultured for 72 hours at 37 ° C., 5% CO 2, and saturated conditions. Cell Counting Kit-8 (DOJINDO) was added at 10 ⁇ l / well, mixed, and then cultured at 37 ° C., 5% CO 2, under saturated room conditions for 2 hours. After measuring the absorbance with Microplate Reader MTP-310 Lab (COLONA ELECTRIC), the IC50 value was calculated.
- FIG. 23A The experimental results are shown in FIG.
- the Kelly cell line had an IC50 of 0.09 nM and the SK-N-SH cell line had an IC50 of 0.13 nM
- the wild-type neuroblastoma IMR-32 cell line IC50 is 0.46 nM
- SK-N-AS cell line has an IC50 of 2.6 nM
- MDA-MB-231 cell line which is a breast cancer cell (ALK gene wild type) without F1174L mutation has an IC50 of 7.5 nM ( Figures 23A-D, Table 5).
- ALK-FL-1 showed stronger and more specific growth inhibition against the neuroblastoma cell line having the F1174L mutation.
- the PIK3CA gene has mutations concentrated in three hot spots, E545K, E542K, which is the helical domain of exon 10, and H1047R, which is the kinase domain of exon 21, and these mutations include breast cancer, colon cancer, endometrial cancer, It has been reported to occur frequently in liver cancer and glioblastoma.
- PIK3CA gene amplification without point mutation has been observed in cervical cancer, lung cancer, gastric cancer, ovarian cancer, and head and neck cancer.
- PIK3CA gene acts as a cancer driver gene in the PI3 kinase-Akt pathway, PI3K inhibitors targeting the PIK3CA gene have been developed, but the current situation is that they have not yet reached clinical application due to toxicity problems and the like. .
- An E545K (1633G> A) mutation in the PIK3CA gene has been observed in the breast cancer cell line MCF7. Therefore, 9-base-recognized PIP-indole-secoCBI compounds P3A-E5K-1 and P3A-E5K-2 that specifically recognize this mutant sequence were synthesized by the same method as the synthesis of KR12 (FIG. 24).
- Cytotoxicity test for breast cancer cells and measurement experiment of 50% inhibitory concentration (IC50) were performed in the same manner as in the case of using KR12.
- the cells used in the experiment were MCF7 cells and MDA-MB-231 cells, which were cultured in DMEM, 10% FBS, 1% Pen / St medium and RPMI 1640, 10% FBS, 1% Pen / St medium, respectively.
- Each cell was seeded in a 96-well plate at 1000 cells / 50 ⁇ l / well, cultured at 37 ° C., 5% CO 2, under saturated conditions for 24 hours, and then the reagent (final concentration 1, 3, 10, 30, 100 nM) in Medium. After dilution, 50 ⁇ l / well was added and mixed.
- the cells were again cultured for 72 hours at 37 ° C., 5% CO 2, and saturated conditions.
- Cell Counting Kit-8 (DOJINDO) was added at 10 ⁇ l / well, mixed, and then cultured at 37 ° C., 5% CO 2, under saturated room conditions for 2 hours. After measuring the absorbance with Microplate Reader MTP-310 Lab (COLONA ELECTRIC), the IC50 value was calculated.
- P3A-E5K-1 had an IC50 of 53.8 nM and P3A-E5K-2> 100 nM, compared to MCF7, a breast cancer cell line having a mutation of E545K (1633G> A) in the PIK3CA gene (FIG. 27A). Compared to MDA-MB-231, a breast cancer cell line in which the PIK3CA gene is wild type, P3A-E5K-1 had an IC50 of> 100 nM (FIG. 27B).
- the P3A-E5K-1 prepared against the E545K mutant cancer cell line of the PIK3CA gene is significantly stronger than the breast cancer cell line having a tumor growth inhibitory effect which is significantly different from the E545K mutant breast cancer cell line. Became clear.
- Cancer cell-specific mutations include gene amplification that is not point mutations or translocations but changes in gene sequence. This is called a copy number change mutation, and a specific cancer-related gene region is amplified, and as a result, the expression level of the oncogene is increased to promote canceration.
- a compound that alkylates a specific genomic sequence as in the present invention is effective even when it is produced by targeting a gene that has been amplified and increased in copy number.
- MYCN alkylated PIP (MYCNA1, MYCNA2, MYCNA3) targeting MYCN, which is a poor prognosis factor, was synthesized.
- the MYCN gene is a gene that is frequently amplified in neuroblastoma, and is considered to be a driver oncogene gene of neuroblastoma.
- a PIP-indole-secoCBI compound (MYCNA1, MYCNA2) that recognizes 8 bases and a 9-base recognition PIP-indole-secoCBI compound that specifically recognizes the sequence of exon 3 ( MYCNA3) (FIG. 28) was synthesized in the same manner as KR12.
- alkylated PIP (MYCNA1, MYCNA2, MYCNA3) of MYCN gene
- the chemical structure of alkylated PIP (MYCNA1, MYCNA2, MYCNA3) of MYCN gene is represented by the following chemical formula.
- the method for producing the compound of the present invention is as follows. PIP having a carboxylic acid end was dissolved in 100 ⁇ L of DMF, and iPr2NEt (0.5 ⁇ L, 2.86 ⁇ mol) and PyBOP (1.0 mg, 1.95 ⁇ mol) were added. After reacting the reaction solution at room temperature for 2 hours with stirring, it was confirmed by HPLC whether or not an active form of 1-hydroxybenzotriazole ester was formed.
- the cells used in the experiment were neuroblastoma cell lines IMR-32 cells (MYCN25 copies) and TGW cells (MYCN60 copies) in which amplification of the MYCN region was observed, and each was DMEM, 10% FBS, 1% Pen / St medium. , RPMI1640, 10% FBS, 1% Pen / St medium.
- Cytotoxicity test for neuroblastoma cells and measurement experiment of 50% inhibitory concentration (IC50) were performed in the same manner as in the case of using KR12.
- the cells used in the experiment were IMR-32 cells and TGW cells, which were cultured in DMEM, 10% FBS, 1% Pen / St medium, RPMI 1640, 10% FBS, 1% Pen / St medium, respectively.
- Each cell was seeded in a 96-well plate at 1000 cells / 50 ⁇ l / well, cultured at 37 ° C., 5% CO 2, under saturated conditions for 24 hours, and then the reagent (final concentration 1, 3, 10, 30, 100 nM) in Medium. After dilution, 50 ⁇ l / well was added and mixed.
- the cells were again cultured for 72 hours at 37 ° C., 5% CO 2, and saturated conditions.
- Cell Counting Kit-8 (DOJINDO) was added at 10 ⁇ l / well, mixed, and then cultured at 37 ° C., 5% CO 2, under saturated room conditions for 2 hours. After measuring the absorbance with Microplate Reader MTP-310 Lab (COLONA ELECTRIC), the IC50 value was calculated.
- the experimental results are shown in FIG.
- the IC50 of MYCNA1 for IMR-32 cells was 9.7 nM and for TGW cells was 12.9 nM.
- the IC50 of MYCNA2 for IMR-32 cells was 12.1 nM and for TGW cells was 11.2 nM. That is, MYCNA1 and MYCNA2 are considered to be capable of inducing growth inhibition of cancer cells in which the expression of the MYCN gene is high at a low concentration.
- FIG. 34 shows that using MYCNA3, IMR-32 cells (with MYCN amplification, neuroblastoma cells), TGW cells (with MYCN amplification, neuroblastoma cells), NB69 cells (without MYCN amplification, neuroblastoma cells) , MCF7 cells (breast cancer cells), HT29 cells (colon cancer cells), HDF cells (corneal epithelial skin fibroblasts) 50% inhibitory concentration (IC50) measurement results and Incubate culture time-lapse microscope (Essen Instruments, Ann Arbor, (MI) is the result of observation of cell proliferation (72 hours after MYCNA3 treatment). Table 6 shows the results of the cell proliferation measurement test performed under the treatment conditions of 0.3 to 300 nM for 72 hours.
- IC50 was 1.1 nM for IMR-32 cells, 3.7 nM for TGW cells, 77.0 nM for MB69 cells, 152.2 nM for MCF7 cells, 239.6 nM for HT29 cells, and 56.6 nM for HDF cells.
- the cell growth inhibitory effect of MYCNA3 is particularly high in neuroblastoma cells with MYCN amplification, and the effect is low in other cancer types, neuroblastoma in which MYCN amplification is not observed, and cell lines derived from normal tissues. Okay ( Figure 34, Table 6).
- SEQ ID NO: 1 synthetic DNA
- SEQ ID NO: 2 synthetic DNA
- SEQ ID NO: 3 synthetic DNA
- SEQ ID NO: 4 synthetic DNA
- SEQ ID NO: 5 synthetic DNA
- SEQ ID NO: 6 synthetic DNA
- SEQ ID NO: 7 synthetic DNA
- SEQ ID NO: 8 synthetic DNA
- SEQ ID NO: 9 synthetic DNA
- SEQ ID NO: 10 synthetic DNA
- SEQ ID NO: 11 synthetic DNA
- SEQ ID NO: 12 synthetic DNA
- SEQ ID NO: 13 synthetic DNA
- SEQ ID NO: 14 synthetic DNA
- SEQ ID NO: 15 synthetic DNA
- SEQ ID NO: 16 synthetic DNA
- Sequence number 17 Synthetic DNA.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
(1)ドライバーオンコジーンの遺伝子変異部位に特異的に結合するDNA結合化合物と、アルキル化剤との複合体。
(2)遺伝子変異部位が遺伝子配列の変化及び/または遺伝子コピー数の変化である、(1)に記載の複合体。
(3)ドライバーオンコジーンが、KRAS、HRAS、NRAS、BCR−ABL、EGFR、c−KIT、BRAF、PI3K、ALK、PIK3CA、FLT3、MET、BCL2、EML4‐ALK、APC、BRCA1/2、TP53、MSH2、MLH1、MSH6、PMS2、RB1、PTEN、VHL、P16、MEN1、RET、CDH1、STK11、PTCH、Her2/neu、EGFR、MYC、MYCNおよびMET、並びに癌の遺伝子変異データベースに登録される遺伝子から選ばれる少なくとも1つである、(1)および(2)のいずれか1つに記載の複合体。
(4)DNA結合化合物がBridged Nucleic Acid(架橋化核酸)、Locked Nucleic Acid(LNA)、PNA、DNA結合蛋白複合体、ピロール・イミダゾールポリアミド(PIP))、ピロール・イミダゾールポリアミド(PIP)修飾物またはDNA結合蛋白もしくはその複合体である、(1)~(3)のいずれか1つに記載の複合体。
(5)アルキル化剤が、DNAの特定の塩基配列に対して、アルキル化能を有する官能基を有する化合物である、(1)~(4)のいずれか1つに記載の複合体。
(6)アルキル化剤がsecoCBIである、(5)に記載の複合体。
(7)(1)~(6)のいずれか1つに記載の複合体を含む、ドライバーオンコジーン遺伝子変異特異的アルキル化剤。
(8)下式で表される(1)に記載の複合体。
(15)(9)に記載の複合体を含むALK遺伝子F1174L変異アルキル化剤。
(16)(10)および(11)のいずれか1つに記載の複合体を含むPIK3CA遺伝子E545K変異アルキル化剤。
(17)(12)および(13)のいずれか1つに記載の複合体を含むMYCN遺伝子増幅変異アルキル化剤。
(18)(1)~(6)および(8)~(13)のいずれか1つに記載の複合体を含む医薬組成物。
(19)医薬組成物が抗癌剤である(18)に記載の医薬組成物。
(20)(1)~(6)および(8)~(13)のいずれか1つに記載の複合体を含むキット。
(21)(1)~(6)および(8)~(13)のいずれか1つに記載の複合体を含む研究試薬キット。
(22)(1)~(6)および(8)~(13)のいずれか1つに記載の複合体を含む治療用キット。
(23)(1)ドライバーオンコジーンの遺伝子変異部位に特異的に結合するようにDNA結合化合物を設計する工程、
(2)設計したDNA結合化合物とアルキル化剤とを結合させる工程を含む、
ドライバーオンコジーンの遺伝子変異部位を特異的にアルキル化する複合体の製造方法。
(24)遺伝子変異部位が遺伝子配列の変化または遺伝子コピー数の変化である、(23)に記載の製造方法。
(25)ドライバーオンコジーンが、RAS、KRAS、HRAS、NRAS、BCR−ABL、EGFR、c−KIT、BRAF、PI3K、ALK、PIK3CA、FLT3、MET、BCL2、EML4‐ALK、APC、BRCA1/2、TP53、MSH2、MLH1、MSH6、PMS2、RB1、PTEN、VHL、P16、MEN1、RET、CDH1、STK11、PTCH、Her2/neu、EGFR、MYC、MYCNおよびMET、並びに癌の遺伝子変異データベースに登録される遺伝子からなる群から選ばれる少なくとも1つである、(23)または(24)に記載の製造方法。
(26)DNA結合化合物がBridged Nucleic Acid(架橋化核酸)、Locked Nucleic Acid(LNA)、PNA、DNA結合蛋白複合体、ピロール・イミダゾールポリアミド(PIP))、ピロール・イミダゾールポリアミド(PIP)修飾物またはDNA結合蛋白もしくはその複合体のいずれかである、(23)~(25)のいずれか1つに記載の製造方法。
(27)アルキル化剤が、DNAの特定の塩基配列に対して、アルキル化能を有する官能基を有する化合物である、(23)~(26)のいずれか1つに記載の複合体の製造方法。
(28)アルキル化剤がsecoCBIである、(27)に記載の製造方法。
(29)(23)~(28)のいずれか1つに記載の製造方法で得られた複合体の医薬組成物の製造のための使用。
(30)(23)~(28)のいずれか1つに記載の製造方法で得られた複合体の抗癌剤の製造のための使用。
KRAS遺伝子のコドン12の変異は、現在、最も治療の困難な膵臓癌に多く見られるほか、化学療法抵抗性の転移を有する大腸癌患者または肺癌患者にも見られる遺伝子変異である。現在、KRAS遺伝子のコドン12変異に対する有効な治療薬が望まれている。本実施例では、KRAS遺伝子のコドン12の変異配列を標的とするヘアピン型PIP(hPIP)にDNA塩基の副溝側のアデニンを特異的にアルキル化するsecoCBIを縮合させることでKRAS遺伝子のコドン12の変異を特異的に認識するhPIP−secoCBI(KR12)を合成した。KR12を用いて、(1)KRAS遺伝子コドン12変異の塩基配列のアルキル化確認実験、(2)大腸癌細胞に対する50%阻害濃度の測定、(3)細胞増殖及び細胞形態の観察、(4)細胞周期変化の解析、(5)半定量的遺伝子発現解析、(6)コロニーシークエンス、(7)RAS活性測定、(8)癌細胞を移植したヌードマウスの腫瘍抑制評価実験(9)がん細胞およびスフェア形成細胞への取り込みと薬剤排泄メカニズムからの回避の確認実験(10)腫瘍細胞核内への集積性の確認実験を行った。
KRAS遺伝子のコドン12変異アルキル化PIP(KR12)の化学構造は以下の化学式14で表される。本発明の化合物の作製方法は以下のとおりである。カルボン酸末端を持つPIPをDMF100μLに溶解し、iPr2NEt(0.5μL、2.86μmol)とPyBOP(1.0mg、1.95μmol)を加えた。反応溶液を撹拌しながら室温で2時間反応させた後、1−ヒドロキシベンゾトリアゾールエステルの活性体が出来ているかをHPLCで確認した。確認後、NH2−インドールseco−CBI(0.6mg、1.58μmol)を反応容器に加え、室温、窒素雰囲気下で一晩撹拌し、溶媒であるDMFを除き、残渣をジクロロメタンとジエチルエーテルで分液した。反応物の層はHPLCにより精製し(0.1%TFA/CH3CN、30−75%リニアグラジエント、0~30分間)、凍結乾燥により目的化合物であるKRAS遺伝子のコドン12変異アルキル化PIポリアミド(KR12)が白い粉末で得られた(LC−MSm/e C89H94ClN31O16[M+2H]2+ 計算値:943.86、実測値944.25、図3)。
また、上述の方法を適用して、下記の化学式15で表されるKRAS遺伝子のコドン12と野生型の配列を認識しないコドン13変異を標的にしたアルキル化PIP(KR13)も合成した(図4)。そして、下記の化学式16、17に示す通り、KRAS遺伝子の野生型コドン12の塩基配列を認識するWT(図5)、KR12からアルキル化能を持つCBI基を除いたC12−Dpも合成した(図6)。
(1)プラスミドDNAのクローニング
25μMの2つの断片対(5’−GCCTACGCCATCAGCGCTGTTGGCGTAGGCA−3’(配列番号1)、3’−ACGGATGCGGTAGTCGCGACAACCGCATCCG−5’(配列番号2))を含む最終容量50μLをアニールしてDNA断片を得た。アニール化された断片をSigma−Aldrich製のpGEM−T easy vectorsに連結した。産物をプロメガ製のEscherichia・Coli(JM109)コンピテントセルに形質転換し、100μg/mLのアンピシリンを加えたLB培地のプレートで37℃、一晩培養した。目的の形質転換されたホワイトコロニーは500nMのプライマーセット(T7:5’−TAATACGACTCACTATAGG−3’(配列番号3)、sp6:5’−CATACGATTTAGGTGACACTATAG−3’(配列番号4))とプロメガ製の1U GoTaq(R) Green Master Mixを含む10μLの反応溶液を用いたコロニーダイレクトPCRにより同定した。増幅サイクルは以下のように行った。反応溶液を95℃で2分間インキュベートした後、95℃で30秒、55℃で30秒、72℃で30秒間の反応サイクルを30回繰り返した後に最後の伸長反応を72℃で7分間の反応サイクルで行った。コロニーは100μg/mLのアンピシリンを含む5mLのLB培地に移し、37℃で一晩培養した。この導入されたプラスミドはシグマアルドリッチ製のGenElutePlasmid miniprep kitにより回収した。
5’末端がテキサスレッドで標識された213塩基対のDNA断片を上記で作成したプラスミドとプライマー(sp6:5’−ATTTAGGTGACACTATAG−3’(配列番号5)、T7:5’−TAATACGACTCACTATAGGG−3’(配列番号6)、5’末端はテキサスレッド標識)で合成した。得られた5’末端がテキサスレッドで標識されたDNA断片をシグマ製のPCR−Clean Up Kitで精製し、濃度をUV吸収により決定した。各種アルキル化PIPを含む10μLの反応溶液(5’末端がテキサスレッドにより標識された二本鎖DNA断片10nMと5mMのリン酸ナトリウム緩衝液(pH7.0))を23℃で17時間インキュベートした。反応後、過剰なアルキル化PIPを10mg/mLのcalfthymus DNA(1μL)で除去し、95℃で10分間加熱することで標的アルキル化部位でのDNAの切断を引き起こした。減圧蒸留で溶媒を除去した後、7μLのloading dyeを加える。このサンプルを95℃で25分間加熱した後、迅速に氷上で冷却した。1.2μLのサンプルをHitachi5500−S DNA Sequencerにセットした6%の変性ポリアクリルアミドゲルに乗せ電気泳動を行った(図7)。
LS180大腸細胞株を用い3000~5000個の細胞/ウェルになるように96穴マイクロプレートの1ウェル毎に細胞を播いて、一晩培養した。翌日、コドン12の変異を認識するKR12、野生型KRASを認識するWT、アルキル化剤を付加していないKR12と同様の構造を持つC12−Dpを1nM、10nM、30nM、100nM、300nM、1μMの濃度でそれぞれ細胞に添加、48時間処理した。その後、cell counting kit−8(DOJINDO)を用いて、WST−8試薬を1ウェル毎に添加して、2時間反応させた後、マイクロプレートリーダーで450nmの波長で比色分析法によって細胞数を計測した。細胞数の計算方法は、1)Mediumのみの平均値をだす、2)各ウェルからmediumの平均値を引く、3)DMSOの平均値をだす、4)Medium引いた値をDMSOの平均値で割る×100、5)各処理区の平均値と標準偏差をだし、グラフ作成を行った。IC50計算式は、IC50=10(LOG(A/B)×(50−C)/(D−C)+LOG(B))、A:50%を挟む高い濃度、B:50%を挟む低い濃度、C:Bでの阻害率、D:Aでの阻害率を用いた。
大腸がん及びすい臓がん細胞株を用い3000~5000個の細胞/ウェルになるように96穴マイクロプレートの1ウェル毎に細胞を播いて、一晩培養した。翌日、1nM、10nM、30nM、100nM、300nM、1μMの濃度のコドン12の変異を認識するKR12でそれぞれの細胞を48時間処理した。その後、cell counting kit−8を用いて、WST−8試薬を1ウェル毎に添加して、2時間反応させた後、マイクロプレートリーダーで450nmの波長で比色分析法によって細胞数を計測した。細胞数の計算方法は、1)Mediumのみの平均値をだす、2)各ウェルからmediumの平均値を引く、3)DMSOの平均値をだす、4)Mediumを引いた値をDMSOの平均値で割る×100、5)各処理区の平均値と標準偏差をだし、グラフ作成を行った。IC50計算式は、IC50=10(LOG(A/B)×(50−C)/(D−C)+LOG(B))、A:50%を挟む高い濃度、B:50%を挟む低い濃度、C:Bでの阻害率、D:Aでの阻害率を用いた。
実験結果を表1に示した。KR12に対するIC50について、SW480、SW620、SNU−C2B、LS180、HCT116は低い値を示し、SW1463、DLD−1、HT29、Caco−2は高い値を示した。つまり、KR12が認識するコドン12の変異を持つ細胞株では、IC50が100nM以下の低い値を示した。SW1463、DLD−1、HT−29、Caco−2はKR12が認識するコドン12の変異を持たない細胞株であり、これらのIC50は100nM以上の値を示した。図9に、KR12が認識するコドン12の変異を持たないHT29、Caco2、SW1463と変異を持つSW480、SW620、LS180の濃度依存的細胞増殖抑制効果のグラフを示した。
細胞周期を観察するために、処理した細胞と未処理の細胞をDNaseフリーのPBSで2回洗浄した後、70%エタノール(冷凍)で固定した。固定した細胞は、10g/mL RNaseA、50g/mL ヨウ化プロピジウムを含むPBSで暗所に室温、30分間放置して処理した。FACS Calibur flowcytometer(Becton Dickinson,USA)のFL−2Hフィルターを用いて蛍光強度を測定した。細胞周期の比率は、得られたデータをCell Quest software(Becton Dickinson,USA)で分析して決定した。細胞処理は、LS180を50nM(0.125%DMSOに溶解)のKR12、KR13で72時間処理及び長期処理実験として14日間培養実験を行った。コントロールは10%FBS、0.125%DMSOを含むMEM培地で14日間培養した。
細胞処理は、LS180を1.0×105cells/30mm dishでMEM(gibco)+10%FBS(gibco)+100units/ml Penicillin+100μg/ml Streptmycin(gibco)培養液で培養、50nM(0.125%DMSOに溶解)のKR12、KR13で長期処理実験として14日間培養実験及び72時間投与後、コントロール10%FBS、0.125%DMSOを含むMEM培地で11日間培養した群並びにコントロールの10%FBS、0.125%DMSO投与14日培養群で検討した。それぞれの群の細胞をトリプシン処理後、細胞を回収、50μlのPBS溶液に撹拌、3μlの1.5%TritonX(in water)と3μlのRNase(1mg/ml in water)を加え37°Cで30分間処理、つぎに3μlのproteinase K(1mg/ml)を加え37°Cで30分間処理、さらに12μlの6xloading bufferを加え、65°Cで10分間処理後すぐに20μlを2%アガロースゲルでTBE液、100Vで電気泳動し、エチジウムで染色した。
50nM(0.125%DMSOに溶解)のKR12、KR13の14日間の長期投与実験後のLS180細胞を1×SDS−sample bufferに溶解、100度で5分処理後、蛋白量をBradford reagent(Bio−Rad,CA)で判定、10%SDS−PAGEで泳動後、polyvinylidene difluoride membranes(Millipore,MA)にトランスファーし、5%dry milkをTris−buffered saline(TBS)plus0.1%Tween20をブロッキング剤として、anti−γH2AX(2F3,BioLegend,CA)、anti−p53(DO−1,Santa Cruz Biotechnology,CA)、anti−PARP(Cell Signaling Technologies,MA)、もしくはanti−actin antibody(20−33,Sigma,MO)をそれぞれ加え、さらにHRP−conjugated anti−mouse IgGもしくはanti−rabbit IgG(Cell Signaling Technologies,MA)で処理した。2次抗体処理前に適宜1次抗体の洗浄を行った。その後TBS plus0.1%Tween20で洗浄し、ECL化学発光(Amersham Biosciences,NJ)で蛋白質を同定した。
HT29、LS180を12穴プレートで培養した。翌日、細胞を50nMのKR12、KR13で処理した後、48時間培養して、細胞を集めてRNAを抽出した。前記抽出にはRNeasy mini kit (Qiagen,CA)RT−PCRを用いた。次に、抽出した前記RNAをテンプレートにSuper Script VILO cDNA Synthesis Kit(Invitrogen,CA)に従って逆転写用のcDNAを調製した。前記cDNAをテンプレートにPCRのは94℃で5分間の後、94℃で30秒、55℃で30秒、72℃で30秒を20サイクル、最後に72℃で7分間の伸長反応を行った。PCR産物は2%アガロースゲルで電気泳動分析を行った。PCR産物量はエチジウムブロマイドで染色した写真によって算出した。
PCRには下記のプライマーセットを使用した。
KRAS遺伝子
フォワードプライマー(センス):
リバースプライマー(アンチセンス):
RPS18(内部標準)
フォワードプライマー(センス):
リバースプライマー(アンチセンス):
6.5×104個の細胞を播いて、一晩培養した後、細胞を50nMのKR12、KR13で処理した後、48時間培養して、細胞を集めてRNAを抽出した。前記抽出にはRNeasy mini kit (Qiagen,CA)RT−PCRを用いた。次に、抽出した前記RNAをテンプレートにSuper Script VILO cDNA Synthesis Kit(Invitrogen,CA)に従って逆転写用のcDNAを調製した。前記cDNAをテンプレートに配列番号7及び配列番号8のプライマーを用い、PCRは94℃で5分間の後、94℃で30秒、55℃で30秒、72℃で30秒を20サイクル、最後に72℃で7分間の伸長反応を行った。PCR産物は、pGEM−T Easy vector(Promega,WI)を用いてクローニングした。そして、大腸菌DH5αコンピテント細胞(Toyobo,Japan)に形質転換し、形質転換体を50μg/mLアンピシリン、1mg X−gal、1mgイソプロピル−β−チオガラクトピラノシドを含むLBプレートで37℃、一晩培養した。白いコロニーをコロニーダイレクトPCRによって同定した。PCR反応のサイクルは94℃で5分間の後、94℃で30秒、55℃で30秒、72℃で30秒を30サイクル行って、最後に72℃で7分間の伸長反応を行った。下記のプライマーセットM13−F1プライマーとM13−R1プライマーを増幅に使用した。増幅したDNAを、シークエンサーでシークエンス用プライマーKRAS−2Rを用いて配列を解読し、一つ一つのコロニーのKRAS遺伝子変異部位を同定した。
KRASコドン12のGAT変異遺伝子(KRAS−MUT−FとKRAS−MUT−R)と野生型遺伝子(KRAS−WT−FとKRAS−WT−R)を特異的に増幅するプライマーを用いて直接前記白いコロニーの大腸菌細胞を用いてPCRを行い、目的のバンドがどちらのプライマーセットで増幅するかで、変異KRAS遺伝子か野生型かをコロニーごとに判断した。
allele specific primer(GAT変異認識)
KRAS−WT−F:
KRAS −WT−R:
KRAS−MUT−F:
KRAS−MUT−R:
2×106cells/100mmプレートまたは1×106cells/100mmプレートの細胞数を完全栄養培地で培養し、翌日、細胞を50nMのKR12、KR13で処理し、48時間培養した後、細胞をマグネシウム溶解バッファー(MLB)に溶解し、RAS activation assay kit(Millipore,MA)を使ってRAS活性レベルを測定した。
細胞を含む下記3種類のPBS溶液をヌードマウスの大腿部の皮下に移植した後(HT29を7匹、LS180を7匹、SW480を6匹)、腫瘍が生着し、腫瘍容積が約100mm3になった時点で、3.4mmolのKR12(1.36mMのKR12をDMSO2.5μLとPBS197.5μLに溶解)、DMSO/PBSコントロール(DMSO2.5μLとPBS197.5μL)の各組成で薬剤を調整し、10分間ソニケーション後、200μLをマウス尾静脈より投与した。体重、腫瘍の大きさは3日に1回計測し、腫瘍の大きさは0.52×L×W×D(1/6×π×L×W×D)の方法で測定した。
HT29(KRAS−WT):(2×106cells/100μlPBSを皮下に移植、KRASコドン12野生株でコドン12の変異を持たない細胞株)
SW480(KRAS−MUThomo):(5×106cells/100μlPBSを皮下に移植、KRAS遺伝子コドン12変異G12Vをホモでもつ細胞株)
LS180(KRAS−MUThetero):(3×106cells/100μlPBSを皮下に移植、KRAS遺伝子コドン12変異G12Dをヘテロでもつ細胞株)
C12DPのN末端にβアラニンを導入し、続いてFITCのカップリングを行った。FITCのカップリングは、4倍過剰のフルオレセイン(0.40mmol)及びDIEA、HCTUをDMFに溶解したものをカラムに通して60分振とうして行った。LS180細胞は、MEM(gibco)+10%FBS(gibco)+100units/ml Penicillin+100g/ml Streptmycin(gibco)培養液で培養し、約50%コンフルエンスの状態で、FITC標識したKR12(1μMol)を添加し、2時間後に封入(VECTOR VECTASHIELD)し、DAPIによる核染色を行いコンフォーカル顕微鏡(Leica TCS−SPE)で観察した。
2種類の大腸がん細胞株SW480細胞とLoVo細胞を用いて実験を行った。それぞれ2×105個をSphere forming Medium(SFM:DMEM/Ham‘s F−12培養液にB27(ミルテニー社、2%)、EGF(20ng/mL)、FGF2(20ng/mLを添加した培養液)とともに培養し、4日目にFITC標識したKR12(1μMol)もしくはDoxisorbicin(1μMol)を添加し、一時間後にPBSで2度洗浄し、再びSFMで培養を始め、0時間、4時間、24時間に封入し(Invitrogen:ProLong(R) Gold Antifade Reagent(With DAPI))、コンフォーカル顕微鏡(Leica TCS−SPE)で観察した。
4週齢で購入したメスBALB/c(nu/nu)マウスに対し、5週齢時に5x106のSW480細胞を皮下に移植後、腫瘍が直径15mmに達した時にFITC標識したKR12(10nmolを1.25%DMSO(200μl)に溶解)もしくはFITC(1mg/kgを1.25%DMSO(200μl)に溶解)、1.25%DMSOを200μl尾静脈より投与し、インビボイメージングシステム(NIPPON ROPER:Lumazone FA)で0時間から2時間おきに10時間まで撮影し、1日後3日後にも蛍光レベルとマウス個体を撮影した(図18)。さらに同様の処理を行ったマウスを24時間後に解剖し、それぞれの臓器及び腫瘍を取り出し、インビボイメージングシステム(NIPPON ROPER:Lumazone FA)で撮影した(図19)。また同様のヒト大腸がん皮下移植マウスに1mg/kgのFITC標識したKR12(1.25%DMSO(200μl)に溶解)、1.25%DMSOを 200μl尾静脈より投与し、24時間後に腫瘍を摘出しOCTコンパウンドにいれ凍結、10ミクロンの凍結切片をLEICA CM1510Sで作成し、コンフォーカル顕微鏡(Leica TCS−SPE)で観察した(図20)。
ALK遺伝子は、肺癌の原因となる融合遺伝子を形成したり、神経芽腫において、恒常的に活性化する点変異を有し、癌化を促進するドライバーオンコジーン遺伝子である。ALK阻害剤がALK遺伝子の変異を持つ癌細胞に有効であることは知られているが、多くの場合癌細胞はALK阻害剤に耐性となり、再発することが多い。神経芽腫におけるALK遺伝子変異F1174L(3522C>A)は、神経芽腫細胞SK−N−SH、SMS−SAN、KELLY、LAN−1において認められている。そこで、この変異配列を特異的に認識する10塩基認識のPIP−indole−secoCBI化合物ALK−FL−1をKR12の合成と同様の方法で合成した(図21)。
ALK遺伝子のアルキル化PIP(ALK−FL−1)の化学構造は以下の化学式で表される(図22)。本発明の化合物の作製方法は以下のとおりである。F1174L(3522C>A)変異は10塩基を認識するPIP−indole−secoCBIで野生型の5’−TGGTGGTTGA−3’配列の3’側から2番目のグアニンを認識できないピロールを配置することで変異型5’−TGGTGGTTTA−3’を認識させる化合物として設計した。
実験はKR12を用いた場合と同様にして行った。実験に用いた細胞は、Kelly細胞、SK−N−SH細胞、IMR−32細胞、SK−N−AS細胞、MDA−MB−231細胞であり、それぞれDMEM、10%FBS、1%Pen/St培地、RPMI1640、10%FBS、1%Pen/St培地で培養した。96ウェル plateに各細胞を1000cells/50μl/ウェル播種し、37℃、5%CO2、飽湿条件下にて24時間培養した後、Mediumに試薬(final concentration 1,3,10,30,100nM)を希釈後、50μl/ウェル添加、混和した。再び37℃、5%CO2、飽湿条件下にて72時間培養した。Cell Counting Kit−8(DOJINDO)を10μl/ウェル添加、混和後、37℃、5%CO2、飽室条件下にて2時間培養した。Microplate Reader MTP−310 Lab(COLONA ELECTORIC)にて吸光度を測定後、IC50値を算出した。
PIK3CA遺伝子は、エキソン10のヘリカルドメインにあたるE545K、E542Kとエキソン21のキナーゼドメインにあたるH1047Rの3か所のホットスポットに変異が集中し、それらの変異は、乳癌、大腸癌、子宮内膜癌、肝癌および脳膠芽腫で高頻度に生じることが報告されている。一方で点変異を伴わないPIK3CA遺伝子の増幅は、頸癌、肺癌、胃癌、卵巣癌、頭頸部癌で認められている。PIK3CA遺伝子は、PI3キナーゼ−Akt経路で、癌ドライバー遺伝子として働くため、PIK3CA遺伝子を標的にしたPI3K阻害剤が開発されているが、毒性の問題等により未だ臨床応用に至っていないのが現状である。PIK3CA遺伝子のE545K(1633G>A)変異は、乳癌細胞株MCF7で認められている。そこで、この変異配列を特異的に認識する9塩基認識のPIP−indole−secoCBI化合物P3A−E5K−1とP3A−E5K−2をKR12の合成と同様の方法で合成した(図24)。
PIK3CA遺伝子のアルキル化PIP(P3A−E5K−1)の化学構造は以下の化学式で表される。本発明の化合物の作製方法は以下のとおりである(図25、26)。E545K(1633G>A)変異を認識させるため5’−CTCCTGCTTA−3’を認識するPIP−Indole−seco−CBIをデザインした。 この化合物は野生型の5’−CTCCTGCTCA−3’を3`から2番目のシトシンが認識できず、3`のアデニンをアルキル化できないが変異配列ではアルキル化できるよう設計した。
実験はKR12を用いた場合と同様にして行った。実験に用いた細胞は、MCF7細胞、MDA−MB−231細胞であり、それぞれDMEM、10%FBS、1%Pen/St培地とRPMI1640、10%FBS、1%Pen/St培地で培養した。96ウェル plateに各細胞を1000cells/50μl/ウェル播種し、37℃、5%CO2、飽湿条件下にて24時間培養した後、Mediumに試薬(final concentration 1,3,10,30,100nM)を希釈後、50μl/ウェル添加、混和した。再び37℃、5%CO2、飽湿条件下にて72時間培養した。Cell Counting Kit−8(DOJINDO)を10μl/ウェル添加、混和後、37℃、5%CO2、飽室条件下にて2時間培養した。Microplate Reader MTP−310 Lab(COLONA ELECTORIC)にて吸光度を測定後、IC50値を算出した。
癌細胞特異的な変異として、点変異や転座ではなく遺伝子配列の変化を伴わない、遺伝子の増幅がある。これはコピーナンバーチェンジ変異と言われ、特定のがん関連遺伝子の領域が増幅し、結果としてがん遺伝子の発現量が上昇することで癌化を促すものである。我々は本発明のように特定のゲノム配列をアルキル化する化合物が、増幅してコピー数が多くなった遺伝子を標的にして作成した場合も効果を発揮すると考え小児の神経芽腫等で高頻度に増幅し、予後不良因子となるMYCNを標的としたMYCNアルキル化PIP(MYCNA1、MYCNA2、MYCNA3)を合成した。MYCN遺伝子は、神経芽腫において高頻度に増幅する遺伝子で、神経芽腫のドライバーオンコジーン遺伝子と考えられている。このMYCN遺伝子に対し、図2に示ように8塩基を認識するPIP−indole−secoCBI化合物(MYCNA1、MYCNA2)及びエキソン3の配列を特異的に認識する9塩基認識のPIP−indole−secoCBI化合物(MYCNA3)(図28)をKR12の合成と同様の方法で合成した。
MYCN遺伝子のアルキル化PIP(MYCNA1、MYCNA2、MYCNA3)の化学構造は以下の化学式で表される。本発明の化合物の作製方法は以下のとおりである。カルボン酸末端を持つPIPをDMF100μLに溶解し、iPr2NEt(0.5μL、2.86μmol)とPyBOP(1.0mg、1.95μmol)を加えた。反応溶液を撹拌しながら室温で2時間反応させた後、1−ヒドロキシベンゾトリアゾールエステルの活性体が出来ているかをHPLCで確認した。確認後、NH2−インドールseco−CBI(0.6mg、1.58μmol)を反応容器に加え、室温、窒素雰囲気下で一晩撹拌し、溶媒であるDMFを除き、残渣をジクロロメタンとジエチルエーテルで分液した。反応物の層はHPLCにより精製し(0.1%TFA/CH3CN、30−75%リニアグラジエント、0~30分間)、凍結乾燥により目的化合物であるアルキル化PIポリアミド、MYCNA1が白い粉末で得られた(図29)。MYCNA2、MYCNA3も同様の方法で得られた(図30、31)。MYCNを標的としたPIPの設計方法は図2に示されている。
細胞を96穴プレートで1000cells/50μl/ウェル播種し、37℃、5%CO2、飽湿条件下にて24時間培養し、翌日、DMSOコントロール、1nM、3nM、10nM、30nM、100nMのMYCNA1を添加した培養液に取り換え、細胞をIncucyte培養タイムラプス顕微鏡(Essen Instruments、Ann Arbor、MI)で6時間おきに観察した。成長曲線はIncucyte system(Essen Instruments、Ann Arbor、MI)を用いたイメージングプレートから作成した。実験に用いた細胞は、MYCN領域の増幅が見られる神経芽腫細胞株IMR−32細胞(MYCN25コピー)、TGW細胞(MYCN60コピー)であり、それぞれDMEM、10%FBS、1%Pen/St培地、RPMI1640、10%FBS、1%Pen/St培地で培養した。
実験はKR12を用いた場合と同様にして行った。実験に用いた細胞は、IMR−32細胞、TGW細胞であり、それぞれDMEM、10%FBS、1%Pen/St培地、RPMI1640、10%FBS、1%Pen/St培地で培養した。96ウェル plateに各細胞を1000cells/50μl/ウェル播種し、37℃、5%CO2、飽湿条件下にて24時間培養した後、Mediumに試薬(final concentration 1,3,10,30,100nM)を希釈後、50μl/ウェル添加、混和した。再び37℃、5%CO2、飽湿条件下にて72時間培養した。Cell Counting Kit−8(DOJINDO)を10μl/ウェル添加、混和後、37℃、5%CO2、飽室条件下にて2時間培養した。Microplate Reader MTP−310 Lab(COLONA ELECTORIC)にて吸光度を測定後、IC50値を算出した。
配列番号2:合成DNA、
配列番号3:合成DNA、
配列番号4:合成DNA、
配列番号5:合成DNA、
配列番号6:合成DNA、
配列番号7:合成DNA、
配列番号8:合成DNA、
配列番号9:合成DNA、
配列番号10:合成DNA、
配列番号11:合成DNA、
配列番号12:合成DNA、
配列番号13:合成DNA、
配列番号14:合成DNA、
配列番号15:合成DNA、
配列番号16:合成DNA、
配列番号17:合成DNA。
Claims (30)
- ドライバーオンコジーンの遺伝子変異部位に特異的に結合するDNA結合化合物と、アルキル化剤との複合体。
- 遺伝子変異部位が遺伝子配列の変化及び/または遺伝子コピー数の変化である、請求項1に記載の複合体。
- ドライバーオンコジーンが、KRAS、HRAS、NRAS、BCR−ABL、EGFR、c−KIT、BRAF、PI3K、ALK、PIK3CA、FLT3、MET、BCL2、EML4‐ALK、APC、BRCA1/2、TP53、MSH2、MLH1、MSH6、PMS2、RB1、PTEN、VHL、P16、MEN1、RET、CDH1、STK11、PTCH、Her2/neu、EGFR、MYC、MYCNおよびMET、並びに癌の遺伝子変異データベースに登録される遺伝子から選ばれる少なくとも1つである、請求項1および2のいずれか1項に記載の複合体。
- DNA結合化合物がBridged Nucleic Acid(架橋化核酸)、Locked Nucleic Acid(LNA)、PNA、ピロール・イミダゾールポリアミド(PIP)、ピロール・イミダゾールポリアミド(PIP)修飾物、DNA結合蛋白、およびDNA結合蛋白複合体のいずれかである、請求項1~3のいずれか1項に記載の複合体。
- アルキル化剤が、DNAの特定の塩基配列に対して、アルキル化能を有する官能基を有する化合物である、請求項1~4のいずれか1項に記載の複合体。
- アルキル化剤がsecoCBIである、請求項5に記載の複合体。
- 請求項1~6のいずれか1項に記載の複合体を含む、ドライバーオンコジーン遺伝子変異特異的アルキル化剤。
- 請求項8に記載の複合体を含むKRAS遺伝子コドン12変異アルキル化剤。
- 請求項9に記載の複合体を含むALK遺伝子F1174L変異アルキル化剤。
- 請求項10および11のいずれか1項に記載の複合体を含むPIK3CA遺伝子E545K変異アルキル化剤。
- 請求項12および13のいずれか1項に記載の複合体を含むMYCN遺伝子増幅変異アルキル化剤。
- 請求項1~6および8~13のいずれか1項に記載の複合体を含む医薬組成物。
- 医薬組成物が抗癌剤である請求項18に記載の医薬組成物。
- 請求項1~6および8~13のいずれか1項に記載の複合体を含むキット。
- 請求項1~6および8~13のいずれか1項に記載の複合体を含む研究試薬キット。
- 請求項1~6および8~13のいずれか1項に記載の複合体を含む治療用キット。
- (1)ドライバーオンコジーンの遺伝子変異部位に特異的に結合するようにDNA結合化合物を設計する工程、
(2)設計した前記DNA結合化合物とアルキル化剤とを結合させる工程を含む、
ドライバーオンコジーンの遺伝子変異部位を特異的にアルキル化する複合体の製造方法。 - 遺伝子変異部位が遺伝子配列の変化または遺伝子コピー数の変化である、請求項23に記載の製造方法。
- ドライバーオンコジーンが、RAS、KRAS、HRAS、NRAS、BCR−ABL、EGFR、c−KIT、BRAF、PI3K、ALK、PIK3CA、FLT3、MET、BCL2、EML4‐ALK、APC、BRCA1/2、TP53、MSH2、MLH1、MSH6、PMS2、RB1、PTEN、VHL、P16、MEN1、RET、CDH1、STK11、PTCH、Her2/neu、EGFR、MYC、MYCNおよびMET、並びに癌の遺伝子変異データベースに登録される遺伝子からなる群から選ばれる少なくとも1つである、請求項23および24のいずれか1項に記載の製造方法。
- DNA結合化合物がBridged Nucleic Acid(架橋化核酸)、Locked Nucleic Acid(LNA)、PNA、ピロール・イミダゾールポリアミド(PIP)、ピロール・イミダゾールポリアミド(PIP)修飾物、DNA結合蛋白、およびDNA結合蛋白複合体のいずれかである、請求項23~25のいずれか1項に記載の製造方法。
- アルキル化剤が、DNAの特定の塩基配列に対して、アルキル化能を有する官能基を有する化合物である、請求項23~26のいずれか1項に記載の複合体の製造方法。
- アルキル化剤がsecoCBIである、請求項27に記載の製造方法。
- 請求項23~28のいずれか1項に記載の製造方法で得られた複合体の医薬組成物の製造のための使用。
- 請求項23~28のいずれか1項に記載の製造方法で得られた複合体の抗癌剤の製造のための使用。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015541666A JP6705953B2 (ja) | 2013-10-11 | 2014-10-14 | ドライバーオンコジーンの遺伝子変異を標的にアルキル化する新規アルキル化剤 |
EP14851833.5A EP3078661A4 (en) | 2013-10-11 | 2014-10-14 | Novel alkylating agent for alkylating target with driver oncogene mutation |
CN201480067194.5A CN106068266A (zh) | 2013-10-11 | 2014-10-14 | 以癌症驱动基因的基因突变为靶点进行烷基化的新型烷基化剂 |
US15/027,877 US10350300B2 (en) | 2013-10-11 | 2014-10-14 | Alkylating agent for alkylating target with driver oncogene mutation |
US16/377,867 US10751421B2 (en) | 2013-10-11 | 2019-04-08 | Alkylating agent for alkylating target with driver oncogene mutation |
US16/918,692 US11185593B2 (en) | 2013-10-11 | 2020-07-01 | Alkylating agent for alkylating target with driver oncogene mutation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013-214044 | 2013-10-11 | ||
JP2013214044 | 2013-10-11 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/027,877 A-371-Of-International US10350300B2 (en) | 2013-10-11 | 2014-10-14 | Alkylating agent for alkylating target with driver oncogene mutation |
US16/377,867 Division US10751421B2 (en) | 2013-10-11 | 2019-04-08 | Alkylating agent for alkylating target with driver oncogene mutation |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015053413A1 true WO2015053413A1 (ja) | 2015-04-16 |
Family
ID=52813226
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2014/077766 WO2015053413A1 (ja) | 2013-10-11 | 2014-10-14 | ドライバーオンコジーンの遺伝子変異を標的にアルキル化する新規アルキル化剤 |
Country Status (5)
Country | Link |
---|---|
US (3) | US10350300B2 (ja) |
EP (1) | EP3078661A4 (ja) |
JP (1) | JP6705953B2 (ja) |
CN (1) | CN106068266A (ja) |
WO (1) | WO2015053413A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017135311A1 (ja) * | 2016-02-01 | 2017-08-10 | 国立大学法人千葉大学 | 配列特異的で設計可能な標的遺伝子の転写抑制阻害剤およびこれを含む組成物並びにその使用 |
WO2018056361A1 (ja) | 2016-09-21 | 2018-03-29 | 千葉県 | 新規アルキル化剤 |
US11097009B2 (en) | 2015-02-12 | 2021-08-24 | Kyoto University | CTB-PI polyamide conjugate for activating expression of specific gene |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113105623B (zh) * | 2021-03-30 | 2022-08-12 | 杭州庆正鸿科技有限公司 | 一种靶向pd-l1基因的小分子抑制剂及其应用 |
CN115869325A (zh) * | 2021-09-26 | 2023-03-31 | 深圳艾欣达伟医药科技有限公司 | 化合物用于制备治疗kras突变癌症患者的药物的用途 |
WO2023133284A2 (en) * | 2022-01-06 | 2023-07-13 | Design Therapeutics, Inc. | Compounds and methods for treating friedreich's ataxia |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0345706B2 (ja) | 1985-03-15 | 1991-07-11 | Kurimoto Ltd | |
JP2001136974A (ja) | 1999-11-16 | 2001-05-22 | Japan Science & Technology Corp | 生理活性ピロールイミダゾール誘導体のスクリーニング方法 |
WO2003000683A1 (en) | 2001-06-25 | 2003-01-03 | Japan Science And Technology Agency | Method of the solid phase synhesis of pyrrole-imidazole polyamide |
WO2005087762A1 (ja) | 2004-03-13 | 2005-09-22 | Tmrc Co., Ltd. | Dnaの特定塩基配列をアルキル化する新規インドール誘導体ならびにそれを用いたアルキル化剤および薬剤 |
WO2010001933A1 (ja) | 2008-07-01 | 2010-01-07 | 学校法人日本大学 | 標的遺伝子特異的ヒストン修飾制御剤 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9744175B2 (en) * | 2012-04-06 | 2017-08-29 | Indus Pharmaceuticals, Inc. | Compositions of combinations of non-covalent DNA binding agents and anti-cancer and/or anti-inflammatory agents and their use in disease treatment |
-
2014
- 2014-10-14 EP EP14851833.5A patent/EP3078661A4/en not_active Withdrawn
- 2014-10-14 US US15/027,877 patent/US10350300B2/en active Active
- 2014-10-14 JP JP2015541666A patent/JP6705953B2/ja active Active
- 2014-10-14 WO PCT/JP2014/077766 patent/WO2015053413A1/ja active Application Filing
- 2014-10-14 CN CN201480067194.5A patent/CN106068266A/zh active Pending
-
2019
- 2019-04-08 US US16/377,867 patent/US10751421B2/en active Active
-
2020
- 2020-07-01 US US16/918,692 patent/US11185593B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0345706B2 (ja) | 1985-03-15 | 1991-07-11 | Kurimoto Ltd | |
JP2001136974A (ja) | 1999-11-16 | 2001-05-22 | Japan Science & Technology Corp | 生理活性ピロールイミダゾール誘導体のスクリーニング方法 |
WO2003000683A1 (en) | 2001-06-25 | 2003-01-03 | Japan Science And Technology Agency | Method of the solid phase synhesis of pyrrole-imidazole polyamide |
WO2005087762A1 (ja) | 2004-03-13 | 2005-09-22 | Tmrc Co., Ltd. | Dnaの特定塩基配列をアルキル化する新規インドール誘導体ならびにそれを用いたアルキル化剤および薬剤 |
WO2010001933A1 (ja) | 2008-07-01 | 2010-01-07 | 学校法人日本大学 | 標的遺伝子特異的ヒストン修飾制御剤 |
Non-Patent Citations (27)
Title |
---|
AKIHIKO NARITA ET AL.: "Sequence Specific DNA Alkylation and in vivo Gene Silencing by Alkylating Pyrrole-Imidazole Polyamides", CSJ: THE CHEMICAL SOCIETY OF JAPAN KOEN YOKOSHU, vol. 84, no. 2, 2004, pages 1063, XP008183179 * |
BOGER, D. L.; ISHIZAKI, T.; KITOS, P. A.; SUNTORNWAT, O, J. ORG. CHEM., vol. 55, 1990, pages 5823 |
BOGER, D. L.; MCKIE, J. A., J. ORG. CHEM., vol. 60, 1995, pages 1271 |
BOGER, D. L.; YUN, W. Y.; TEEGARDEN, B. R., J. ORG. CHEM., vol. 57, 1992, pages 2873 |
DERVAN, BIOORG. MED. CHEM., vol. 9, 2001, pages 2215 - 35 |
GENGO KASHIWAZAKI ET AL.: "Alkyl-ka PI Polyamide no Seibutsu Kassei Hyoka", CSJ: THE CHEMICAL SOCIETY OF JAPAN KOEN YOKOSHU, vol. 91, no. 3, 2011, pages 735, XP008183177 * |
HANA KUMAMOTO ET AL.: "DNA Hairetsu Tokuiteki Alkyl-ka ni yoru bcr-abl Idenshi Hatsugen Seigyo eno Oyo", CSJ: THE CHEMICAL SOCIETY OF JAPAN KOEN YOKOSHU, vol. 90, no. 3, 2010, pages 750, XP008183183 * |
HIROKAZU IIDA ET AL.: "Recognition of DNA Sequences by Pyrrole-Imidazole Polyamide Rational Drug Design in the Post-Genome Era", JOURNAL OF SYNTHETIC ORGANIC CHEMISTRY, vol. 58, no. 10, 2000, JAPAN, pages 975 - 987, XP008183550 * |
HIROSHI SUGIYAMA ET AL.: "Alkyl-ka Pyrrole-Imidazole Polyamide ni yoru Tailor-made Kogan Zai no Sosei", POLYMER PREPRINTS, vol. 52, no. 13, 2003, JAPAN, pages 3708 - 3709, XP008183610 * |
HIROSHI SUGIYAMA: "Aiming at development of tailor-made anticancer drug, Tan'itsu Bunshi. Genshi Level no Hanno Seigyo", DAI 6 KAI SYMPOSIUM 2 KI TEAM (HEISEI 8 NENDO SAITAKU) KENKYU SEIKA HOKOKU KOEN YOSHISHU HEISEI 14 NEN, 2002, pages 67 - 70, XP008183821 * |
HIROSHI SUGIYAMA: "Gan no Bunshi Hyoteki Ryoho Pyrrole-Imidazole Polyamide ni yoru Idenshi Hatsugen Seigyo", SAISHIN IGAKU, vol. 56, no. 3, 2001, pages 376 - 383, XP008183747 * |
HIROSHI SUGIYAMA: "Gan Ryoiki ni Okeru Drug Delivery System (DDS) DDS ni Okeru Kiban Gijutsu Kaihatsu DNA Hairetsu o Hyoteki to shita DDS", SAISHIN IGAKU, vol. 61, no. 6, 2006, pages 1067 - 1074, XP008183618 * |
HIROSHI SUGIYAMA: "Sentan Biotechnology no Kaihatsu to Oyo Rational Design of Tailor-made Antitumor Agent", KAGAKU KOGYO, vol. 55, no. 4, 2004, pages 291 - 296, XP008183611 * |
ISAO SAITO ET AL.: "Hito Genome Saizensen 21 Seiki wa Idenshi no Jidai II Bu Post Genome no Yukue Post Genome no Seibutsu Yuki Kagaku Idenshi o Target to suru Drug Design", CHEMISTRY SEPARATE, vol. 2001, pages 89 - 110, XP008183565 * |
J. AM. CHEM. SOC., vol. 117, 1995, pages 2479 - 2490 |
MASAFUMI MINOSHIMA ET AL.: "Sequence-specific DNA alkylation and biochemical application", CSJ: THE CHEMICAL SOCIETY OF JAPAN KOEN YOKOSHU, vol. 89, no. 2, 2009, pages 1391, XP008183182 * |
See also references of EP3078661A4 |
SHUNTA SASAKI ET AL.: "Enki Hairetsu Tokuiteki Ninshikino o Yusuru Alkyl-ka Pyrrole-Imidazole Polyamide no Shinki Bunshi Sekkei", ABSTRACTS, SYMPOSIUM ON BIOFUNCTIONAL CHEMISTRY, vol. 22, 2007, pages 92 - 93, XP008185741 * |
SHUNTA SASAKI ET AL.: "New Molecular Design of Hairpin Imidazole-Pyrrole Polyamides Possessing DNA Alkylation Activity", CSJ: THE CHEMICAL SOCIETY OF JAPAN KOEN YOKOSHU, vol. 84, no. 2, 2004, pages 1049, XP008183178 * |
TAKANORI OYOSHI ET AL.: "Regulation of Gene Expresssion by Sequence-Specific Alkylating Polyamide", CSJ: THE CHEMICAL SOCIETY OF JAPAN KOEN YOKOSHU, vol. 83, no. 2, 2003, pages 1127, XP008183180 * |
TOSHIKAZU BANDO ET AL.: "Hairetsu Tokuiteki Alkyl-ka Zai no Iyakuhin to shite no Kanosei", STUDY OF MEDICAL SUPPLIES, vol. 36, no. 1, 2005, pages 1 - 12, XP008183617 * |
TOSHIKAZU BANDO ET AL.: "Pyrrole-Imidazole Polyamide no Koritsuteki na Alkyl-ka ga Motarasu Seibutsu Kassei", ABSTRACTS OF ANNUAL MEETING OF PHARMACEUTICAL SOCIETY OF JAPAN, vol. 124, no. 2, 2004, pages 54, XP008183629 * |
TOSHIKAZU BANDO ET AL.: "The Chemical Biology That Controls DNA Function and Structure", JOURNAL OF SYNTHETIC ORGANIC CHEMISTRY, vol. 63, no. 10, 2005, JAPAN, pages 1016 - 1027, XP008183613 * |
TRAUGER ET AL., NATURE, vol. 382, 1996, pages 559 - 61 |
WAKANA KAWAKAMI ET AL.: "Regulation of Gene Expression by Sequence-Specific Alkylating Polyamide", CSJ: THE CHEMICAL SOCIETY OF JAPAN KOEN YOKOSHU, vol. 81, no. 2, 2002, pages 945, XP008183181 * |
WHITE ET AL., CHEM. BIOL., vol. 4, 1997, pages 569 - 78 |
WHITE ET AL., NATURE, vol. 391, 1998, pages 468 - 71 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11097009B2 (en) | 2015-02-12 | 2021-08-24 | Kyoto University | CTB-PI polyamide conjugate for activating expression of specific gene |
WO2017135311A1 (ja) * | 2016-02-01 | 2017-08-10 | 国立大学法人千葉大学 | 配列特異的で設計可能な標的遺伝子の転写抑制阻害剤およびこれを含む組成物並びにその使用 |
WO2018056361A1 (ja) | 2016-09-21 | 2018-03-29 | 千葉県 | 新規アルキル化剤 |
JP2018052930A (ja) * | 2016-09-21 | 2018-04-05 | 千葉県 | 新規アルキル化剤 |
Also Published As
Publication number | Publication date |
---|---|
EP3078661A4 (en) | 2017-06-07 |
CN106068266A (zh) | 2016-11-02 |
US10350300B2 (en) | 2019-07-16 |
US10751421B2 (en) | 2020-08-25 |
EP3078661A1 (en) | 2016-10-12 |
JP6705953B2 (ja) | 2020-06-03 |
US11185593B2 (en) | 2021-11-30 |
EP3078661A9 (en) | 2017-02-15 |
US20190290773A1 (en) | 2019-09-26 |
US20160310605A1 (en) | 2016-10-27 |
US20200376133A1 (en) | 2020-12-03 |
JPWO2015053413A1 (ja) | 2017-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11185593B2 (en) | Alkylating agent for alkylating target with driver oncogene mutation | |
AU2017310146B2 (en) | Peptide nucleic acid complex having improved cell permeability and pharmaceutical composition comprising same | |
JP6075903B2 (ja) | Pfkfb2阻害剤および抗癌治療法としての使用方法 | |
CN112135907A (zh) | 具有内含体逃逸能力的肽核酸复合物及其用途 | |
TWI723363B (zh) | 用於治療癌症之包含引導rna及內切酶的藥學組成物 | |
CN111388478A (zh) | Ret抑制剂 | |
JP2021014474A (ja) | 抗腫瘍剤、抗腫瘍効果増強剤及び抗腫瘍用キット | |
WO2020020119A1 (zh) | Rip1抑制剂及其在医药中的用途 | |
JP2019519610A (ja) | アルブミンベースのナノ医薬品を使用するための組成物及び方法 | |
JPWO2010113844A1 (ja) | チミジル酸合成酵素に対するRNAi分子およびその用途 | |
US20220281911A1 (en) | Oligonucleotide conjugate compositions and methods of use | |
JP2002524525A (ja) | 合成ポリアミドによる発癌遺伝子HER/2neu発現の制御 | |
WO2016068617A1 (ko) | 폴리올계 삼투압적 폴리디자일리톨 폴리머 유전자 전달체 및 이의 용도 | |
US20150038531A1 (en) | Use of a novel aminopyridine derivative to prevent or treat cancer | |
WO2019230669A1 (ja) | Runx結合配列を標的とする医薬組成物およびrunx阻害剤 | |
CN104225611A (zh) | 达沙替尼与非线性构型聚乙二醇的结合物 | |
WO2021261592A1 (ja) | リピート結合剤 | |
KR101464360B1 (ko) | 리보자임과 shRNA를 함유하는 아데노바이러스 및 이를 포함하는 암 치료용 조성물 | |
WO2018056361A1 (ja) | 新規アルキル化剤 | |
CN116925084A (zh) | 对肿瘤过表达的细胞周期调节蛋白wee1有双重抑制作用的化合物 | |
JP2023510124A (ja) | 細胞外基質及び抗ガン剤からなる接合体及びその医学的用途 | |
BR112016000163B1 (pt) | Estrutura de oligo rna de dupla hélice, nanopartículas, composição farmacêutica e formulação liofilizada |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14851833 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2015541666 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2014851833 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014851833 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15027877 Country of ref document: US |